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ABSTRACT 
Microtubules (MTs) are cytoskeleton components involved in a plenty of cellular 
functions such as transport, motility, and mitosis. Being polymers made up of α/β-tubulin 
heterodimers, in order to accomplish these functions, they go through large variations in 
their spatial arrangement switching between polymerization and depolymerization phases. 
Because of their role in cellular division, interfering with MTs dynamic behavior has 
been proven to be suitable for anticancer therapy as tubulin-binding agents induce mitotic 
arrest and cell death by apoptosis. However, how microtubule-stabilizing agents like taxane-
site ligands act to promote microtubule assembly and stabilization is still argument of debate. 
As in the case of tubulin, traditional docking techniques lack the necessary capabilities 
of treating protein flexibility that are central to certain binding processes. For this reason, 
the aim of this project is to put in place a protocol for dynamic docking of taxane-site ligands 
to β-tubulin by means of enhanced sampling MD simulation techniques. 
Firstly, the behavior of the binding pocket has been investigated with classical MD 
simulations. It has been observed that the most flexible part of the taxane site is the so-called 
“M-loop”, the one involved into the lateral associations of tubulin heterodimers and that is 
supposed to be stabilized by taxane-site ligands. 
Secondly, the protocol for the dynamic docking has been put in place using the MD-
Binding technique developed by BiKi Technologies. It showed to be effective in reproducing 
the binding mode of epothilone A and discodermolide as in their X-ray crystal structures. 
Finally, the protocol has been tested against paclitaxel, a drug for which no X-ray crystal 
structure is currently available. 
These results showed the potential of such an approach and strengthen the belief that in 
the future dynamic docking will replace traditional static docking in the drug discovery and 
development process.   
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1. Introduction 
Proteins are inherently flexible objects, capable of undergoing large motions in their 3D 
structure and adopting different conformations in order to exert their functions. Without this 
capability, almost all the processes crucial for cellular life like cytoplasmic organization, 
metabolism, enzymatic activity, and signal transduction could not be possible. This is mostly 
related to the plethora of partners with whom proteins interact, ranging from ions and 
substrate molecules to small peptides and other proteins. The mechanism by which proteins 
identify their partner(s) is at the foundation of their biological activity and understanding the 
driving forces of this process is mandatory to design new drugs able to inhibit or enforce a 
specific biological process. 
When enough structural data is available, computational techniques applied to the 
pharmaceutical and chemical fields, generally referred as computer-aided drug design 
(CADD) [1], showed to be effective throughout the entire drug discovery and development 
process. Following this process, CADD can be useful from the initial rational identification 
of novel compounds showing some activity against a biological target (hit compounds), in 
the subsequent optimization so as to increase their potency and physicochemical properties 
in vitro (lead compounds), to the final improvement in efficacy and pharmacokinetic 
properties [2] in vivo (drugs). 
Conventionally, the search of hit compounds relied mostly on expensive and time-
consuming biological assays (such as high-throughput screening, HTS [3]). Besides, the 
chemical space that can be screened is limited to the compounds that are present in a 
particular library owned by a company or by an academic institution. On the contrary, the 
availability of virtual libraries let the researchers extend their studies to compounds that do 
not necessarily exist physically but that can be readily obtained through purchase or 
synthesis [4] and, even further, to that chemical space that has not been explored yet [5], nor 
chemically neither computationally. 
However, it has to be stressed that one cannot consider CADD as an alternative to the 
conventional (HTS) assays. Together, the two share strengths and weaknesses and should be 
used in combination so as to improve efficacy reducing the waste of resources in synthesis 
and screening. Taking into account the cases in which CADD helped in the discovering of 
chemical compounds nowadays used in therapy, some examples can be the ACE inhibitor 
Captopril (Bristol Myers-Squibb) and the renin inhibitor Aliskiren (Rasilez, Novartis) used for 
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the treatment of hypertension or the carbonic anhydrase inhibitor Dorzolamide (Merk) used 
against glaucoma eye pathologies [6]. 
In the subsequent pages, molecular docking, one of the most useful application of CADD 
techniques, will be introduced along with the reasons that have made it so popular and the 
reasons why a paradigm shift to dynamic docking is needed in order to deal with protein 
flexibility. 
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1.1. The Traditional Approach to Molecular Docking 
When it comes to discovering novel hit compounds (i.e. compounds that show a first 
weak affinity with their target), virtual screening (VS) by molecular docking is still the 
method of election in structure-based drug discovery (SBDD) [7,8]. Molecular docking is 
an in silico technique that aims at predicting the binding mode of a specified compound 
within the active site of the protein of interest [9]. Thanks to the constant growth of available 
protein structures [10] and to the improvement in algorithms and hardware architectures, 
molecular docking and its fast implementation, high-throughput docking (HTD), has proven 
to be an invaluable tool for drug discovery campaigns [6,11]. It allows the rapid screening 
of large virtual libraries of compounds in a fraction of the time required by in vitro studies. 
Accordingly, only compounds that are likely to have an action against the target of interest 
are selected and move forward to biological tests, thus saving costs and time. Therefore, the 
optimization of the speed in VS approaches is crucial. In order to do so, simpler scoring 
functions are used and some features, necessary for a better accuracy, are omitted or 
underestimated. 
This brings out a number of problematics: 
 Protein flexibility is not treated extensively; 
 Water molecules are treated only implicitly; 
 Only a static picture of the binding process is provided. 
 
As a consequence, especially when dealing with cases in which large target 
rearrangements are observed upon ligand binding [12] or when water molecules are crucial 
for ligand-target complexes, molecular docking shows its weaknesses. Therefore, a reliable 
estimation of key thermodynamic observables and kinetic quantities is not allowed. From 
this point of view, it is worth noting that binding kinetics has emerged as a more reliable 
predictor of in vivo drug efficacy than affinity [13,14] but the static picture provided by 
molecular docking cannot be used to estimate kinetic quantities. 
Back in time, the first attempts of molecular docking were reported by Kuntz and co-
workers in 1982 [9]. Initially, both ligand and protein were treated as rigid bodies but, 
nowadays, almost all docking programs have implemented proprietary algorithms to treat 
the ligand as a full flexible entity. For some of them, a partial flexibility for the receptor can 
be incorporated too [15,16]. It is known, in fact, that residues involved in the catalytic 
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mechanism of enzymes often show some grade of flexibility [17] and different side chains 
conformations must be considered. 
Briefly, a typical docking algorithm can be divided into two distinct steps, the posing 
phase and the scoring phase [18]. 
1.1.1. Posing 
The first one, the posing phase, is entrusted to a searching algorithm, which can be either 
stochastic or deterministic. It takes care of both roto-translational and internal (usually 
conformational) degrees of freedom of the ligand in order to generate a set of reasonable 
conformations at the receptor’s binding site. For practical reasons, mostly due to limited 
computational resources, the early docking implementations commonly dealt with a single 
rigid conformation of the target. However, as already stated, proteins are intrinsically 
dynamic, and it is not wise to neglect their flexibility. 
Among the recent interpretations of protein-ligand recognition mechanism, it is worth 
mentioning the induced-fit model proposed by Koshland in 1958 [19]. According to it, there 
is a mutual adaptation of the two partners upon binding in order to maximize favorable 
contacts and strengthen the interaction. Likewise, another interpretation of binding, the 
conformational selection or population shift model [20,21], thinks of proteins as a 
conformational ensemble. Only upon binding, one of the available conformations is 
thermodynamically selected, resulting in a population shift to a new equilibrium with respect 
to the one in the apo form [22]. 
Nevertheless, it is clear that receptor’s degrees of freedom should be introduced in 
standard docking procedures and a number of strategies have been implemented trying to 
mimic these recognition mechanisms. Unfortunately, due to the computational complexity 
of the problem, receptor and ligand degrees of freedom cannot be sampled simultaneously 
and the above strategies rather than a solution to the problem appear to be as a workaround. 
These strategies can be classified as either single-structure methods or ensemble methods. 
Single-structure methods resemble the induced-fit model in which the binding pocket 
(or, at least, a number of user-preselected residue side-chains) is perturbed on-the-fly after 
ligand binding conformational search. As expected, no large perturbation in protein structure 
is allowed [23]. Alternatively, in ensemble methods, a series of independent docking 
procedures are run on an ensemble of previously generated protein conformations (either 
  
14 
experimentally or theoretically by means of other sampling techniques), in a similar fashion 
to the population shift model. Anyway, the results obtained by induced-fit approaches and 
the information provided by multiple protein conformations must be properly handled to be 
effectively exploited [24–26]. 
1.1.2. Scoring 
The second phase of a docking protocol is mainly related to the evaluation of the binding 
modes obtained during the first phase. Usually searching algorithms provide more than one 
solution, i.e. more than one pose (or binding mode) for a particular protein-ligand complex 
that must be evaluated. At the same time, in the context of VS simulations, all the ligands 
must be ranked according to their propensity to bind the protein of interest in order to 
prioritize only a subset of molecules [27] promoting them to further studies and analysis. 
This task is performed by the scoring functions. 
Generally, the association (noncovalent) between a protein (P) and a ligand (L) to form 
the complex (PL), 
 
𝑃 + 𝐿 ⇆ 𝑃𝐿 (1) 
 
is described by the equilibrium (or association) constant Ka or its reciprocal dissociation 
constant Kd: 
 
𝐾a =
[𝑃𝐿]
[𝑃][𝐿]
=
1
𝐾d
 (2) 
 
The two constants are related to the standard free energy of binding as follows: 
 
∆𝐺b
° = −𝑘B𝑇 ln(𝐾a 𝐶
∘) = 𝑘B𝑇 ln (
𝐾d
𝐶∘
) (3) 
 
where kB is the Boltzmann constant and C° is the standard concentration. As it is 
common to all entropy-related quantities, sampling remains a major problem and together 
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with other approximations, the estimation of the free energy of binding is often a complex 
task. From a statistical mechanics standpoint, equation (3) translates to [28]: 
 
∆𝐺b
° = −𝑘B𝑇 ln (
Z𝑃𝐿
𝑍𝑃𝑍𝐿
𝐶∘)  (4) 
 
where ZPL, ZP, and ZL are the configurational integrals of the bound complex, the protein, 
and the ligand, respectively. For each i-th species, the configurational integral Zi can be 
expressed as [28]: 
 
𝑍𝑖 = ∫ e
−(𝑈(𝐱𝑖)+𝑊(𝐱𝑖))/𝑘B𝑇d𝐱𝑖 (5) 
 
where U(xi) and W(xi) are the potential energy and the solvation free energy of the i-th 
component in the configuration x. At this point, it is evident that both solvation and 
desolvation effects (and the inherent entropy quantities) caused by the binding event must 
be carefully taken into account to evaluate the configurational integrals and the relative free 
energy of binding. 
Unfortunately, as already mentioned, molecular docking procedures aim at being fast 
and the evaluation of these quantities would require more expensive computational 
procedures. Therefore, a number of different strategies have been implemented in order to 
address this daunting task and to reduce the computational burden, mostly introducing 
approximations in solvent treatment (force-field based scoring functions) or by adopting 
phenomenological descriptions (empirical and knowledge-based scoring functions). 
Nowadays, there are a plethora of different scoring functions and the user can decide which 
one (or which combination of them) to use for a specific task (for a comprehensive list, see 
[29]).  
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1.1.3. Combining Docking and Molecular Dynamics Simulations 
To sum up, there are no doubts about molecular docking capabilities at identifying 
crystallographic binding modes and at selecting promising compounds from large databases 
of molecules when protein flexibility does not play a relevant role. Likewise, its limitations 
and weakness regarding scoring and sampling problems are clear when dealing with protein-
ligand complexes that require large loop rearrangements rather than small local movements. 
In principle, all these problems can be overcome by molecular dynamics (MD) simulations 
and related methods [30].  
The initial idea was that of supporting molecular docking with MD simulations with the 
purpose of giving insights into dynamic aspects of the binding event. The serial use of the 
two approaches, in fact, aims at solving the flexibility problem or, at least, making docking 
results less subjected to the protein model(s) used to evaluate ligands binding modes and 
affinities.  
Clearly, MD simulations can be performed prior or after molecular docking and the 
order in which they take place is relative to the issue that one wants to address. In the 
framework of ensemble-based VS, for example, the ensemble of protein conformations is 
generated running MD simulations before doing docking (Figure 1). Doing so, protein 
flexibility is taken into account as a series of different conformations (that are “snapshots”, 
frames of an MD trajectory) against which a series of parallel VS is run. It can be cited the 
“relaxed complex scheme” developed by Lin et al. [31] and improved by Amaro et al. [32] 
according to which a long MD simulation of the protein of interest in the apo-form is run in 
order to extract, at regular intervals, different protein conformations. Subsequently, parallel 
VS are run against each of the extracted MD frames. However, it is not trivial to choose the 
appropriate protein conformations to build the ensemble and, as it has been shown, the use 
of too many conformations could be detrimental rather than useful for VS results [24]. In 
this respect, with the aim of selecting from the MD simulations only that structures that are 
clearly dissimilar so as to reduce redundancy and improve VS efficiency, cluster analysis 
approaches can be very helpful [33–35].  
On the other hand, MD simulations can be started from docking outcomes with the aim 
of validating or refining docking results with higher-level theories or sampling approaches 
(Figure 2). In this case, MD simulations may be useful to address two different problems, 
one related to posing phase and the other related to scoring phase of docking. In respect to 
  
17 
the former, MD simulations can reveal unstable binding modes, helping in filtering out 
physically unreliable docking solutions or even identifying new ones [36–38]. In particular, 
MD simulations allow accounting for protein flexibility and induced-fit effects, although 
only in a second phase. In respect to the latter, instead, MD simulations can be used to refine 
energetics estimated by the simple scoring functions used by docking algorithms, with re-
scoring purposes. A number of re-scoring approaches are currently available, based on 
different theoretical methods [39], but they approach a more rigorous description of binding 
computing energies as ensemble averages. Re-scoring schemes range from partially 
empirical methods such as Linear Interaction Energy (LIE [40]) through to authentic free-
energy approaches such as Free-Energy Perturbation (FEP [41]) or Thermodynamic 
Integration (TI [42]). It has also to be cited the Molecular Mechanics-Poisson-Boltzmann 
Surface Area and Molecular Mechanics-Generalized Born Surface Area (MM-PB/GB SA) 
re-scoring method, maybe the most popular among them as it provides a good balance 
between reasonable accuracy and computational costs [40].  
 
 
Figure 1 – MD simulations are employed for generating a conformational ensemble of protein 
structures. A number of snapshots are selected by cluster analysis and then docking is performed 
against these multiple rigid receptor conformations to evaluate protein flexibility. 
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Figure 2 – MD simulations run after docking with the purpose of refining and rescoring the 
obtained binding modes. 
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1.2. Towards Dynamic Docking 
As it is now clear, standard molecular docking procedures handle the problem of protein 
flexibility only partially or, when combined to MD simulations, in two different moments, 
in a way that protein and ligand degrees of freedom are not treated simultaneously, as it 
should be. At the same time, they lack the required accuracy to obtain a reliable estimation 
of binding free energy and cannot be used to estimate kinetics quantities. Hence, a paradigm 
shift from a static perspective to a dynamic approach of the binding process is now inevitable 
[43,44]. 
With the advent of faster (mainly Graphics Processing Unit (GPU)-based clusters [30]) 
and specific-developed (such as ANTON, design and built by D.E. Shaw Research [31]) 
hardware architectures along with the improvement of computation algorithms, classical 
MD simulations are gaining everyday more importance in drug design and development 
programs. MD simulations are inherently able to deal with the structural flexibility of drug-
target systems at a fully atomistic description [30]. Moreover, on the condition that 
simulations are long enough to cover the entire drug-binding process (i.e., from the drug 
fully solvated in water to the final bound state), thermodynamics and kinetics quantities can 
be evaluated straightforwardly [30,43]. Nowadays, it is possible to reach and sometimes 
exceed milliseconds-long MD simulations [45,46] However, in order to evaluate 
thermodynamics observables and kinetic quantities, the event of interest (i.e. the binding 
event, in this case) has to be observed multiple times along the simulation so as to  thoroughly 
sample the configurational space and collect adequate statistics. This usually requires multi-
milliseconds simulations making the whole process computationally demanding, even when 
studying just a single molecule with the help of specialized hardware. In other words, there 
is a long road ahead before “brute force” plain MD simulations will be routinely used by 
industry in place of standard docking techniques at the beginning of the long drug discovery 
process when novel compounds have to be identified. The same applies when a series of 
compounds in the hit-to-lead optimization have to be evaluated. To overcome these 
limitations, during the last years, a number of different enhanced sampling methods [47] 
have been introduced. These approaches, by applying biasing forces or altering the potential 
energy function allow researchers to accelerate MD simulations increasing the probability 
of observing the event of interest, such as ligand-protein (un)binding. Thanks to these 
approaches and to the ever-increasing computational power, MD simulations are going to 
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replace the old-fashioned view of static molecular docking with a novel concept commonly 
referred as “dynamic docking” [43,44]. 
The main difference in respect to the traditional docking techniques is that dynamic 
docking simulations aim at characterizing the protein-ligand binding process at a fully 
dynamic level. However, similarly to traditional docking methods, there are two issues that 
need to be addressed: the first is related to the ability to generate binding modes, which 
strongly depends on the sampling strategy used (classical unbiased MD simulations vs 
enhanced sampling methods); the second is related to the evaluation of the identified binding 
modes that can be done by estimating the free energy of binding or by relying on statistical 
approaches. 
1.2.1. Unbiased-MD Approaches 
As previously introduced, the improvement in computer architectures (i.e. GPUs, 
specialized hardware or distributed computing networks such as GPUGRID.net) allowed 
several groups reaching and breaking the millisecond barrier in MD simulations timescales. 
Therefore, what ten years ago was no more than a hope, that is simulating a spontaneous and 
unrestricted drug-binding event without applying any bias to the system, has now become 
possible. Unbiased-MD approaches are all that approaches in which the dynamics is not 
altered through the use of external forces. Even though some workarounds have been 
proposed to reduce the required computational none of them relies on enhanced sampling 
methods. 
1.2.1.1. Long Plain MD Simulations 
The first example of a spontaneous drug binding events was reported by Shan et al in 
2011 [48]. The authors randomly placed two Src kinase inhibitors within a simulation box 
together with their target protein and let them freely diffuse to their binding site. Not only 
several spontaneous binding events forming complexes nearly identical to those resolved by 
X-ray crystallography were recorded, but they also identified a previously unknown 
allosteric pocket, underlining the potential of these simulations as a suitable tool in standard 
drug discovery programs. The same trail was trodden by Buch and co-workers in order to 
completely reconstruct the benzamidine to trypsin binding process in terms of the pathway 
and related energetics, giving insights into the mechanism of association of a drug to its 
target without neglecting the intermediate states [49]. Similar works were then conducted 
for membrane receptors (the β-adrenergic GPCRs coupled to agonist and antagonist small 
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molecules [50] and spontaneous binding of tiotropium and acetylcholine to M2/M3 
muscarinic receptors [51]) and, recently, for the purine nucleoside phosphorylase enzyme 
and its picomolar inhibitor, the transition state analog DADMe-immucillin-H [52]. 
Similarly, it has been shown the feasibility of applying unbiased MD simulations in the 
context of fragment-to-lead development [53], where as well as reproducing all the 
crystallographic poses of carboxy-thiophene fragments present in the X-ray structure of 
AmpC β-lactamase, trajectory analysis was able to discriminate distinct binding modes from 
both a thermodynamic and a kinetic standpoint [54]. Hence, this dynamical approach to 
docking shed light on ligands route to binding, helping to characterize the major energetic 
barriers along it and the factors that may be of influence on them such as transient 
interactions, dehydration, ligand geometry, and so on, many of which mistreated by 
traditional docking techniques. As a matter of facts, dynamic docking can also be used to 
reveal binding sites and poses of known binders without having previous knowledge of them. 
As reported by Dror and co-workers, who studied the M2 muscarinic acetylcholine receptor 
along with a number of experimentally identified allosteric modulators for which no crystal 
structure was available. They were able to identify an extracellular-facing vestibule to whom 
several modulators can bind, observing that the binding driving force was a set of cation-π 
interactions rather than the previously proposed aromatic-aromatic contacts. It is worth 
noting that their results were validated by mutagenesis analysis and radioligand binding 
experiments, confirming the predictive power of this kind of simulations [55]. 
Taken as a whole, brute force unbiased-MD simulations set a striking landmark in the 
development of dynamic docking but also pointed out their main limitations. The binding of 
a small molecule to its binding pocket, in fact, can still be considered a rare event especially 
when considering ligands that have unfavorable on-rates (i.e. low kon). To this end, the 
easiest and most popular approach to overcome this hurdle was to place in the simulation 
box more than one ligand molecule, so as to increase the probability of observing a binding 
event. Although this strategy may be of some help, in order to sample thoroughly the 
configurational space and collect enough statistics, multiple long trajectories are still needed. 
Therefore, it is not surprising that most of the above-reported applications took advantage of 
specialized hardware or massive computing architectures to carry out the simulations. That’s 
the reason why, in the context of unbiased simulations, a number of solutions have been 
proposed to bring dynamic docking to a more practical and effective usage. These strategies 
include adaptive sampling methods, supervised approaches, and multiscale modeling. 
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1.2.1.2. Adaptive Sampling Methods 
Adaptive sampling methods entail a class of unbiased-MD approaches relying on the 
framework of Markov State Model (MSM) [56,57]. They aim at identifying under-sampled 
states along the binding process in order to run new simulations from these points (a process 
usually termed “seeding”) so as to lower the statistical error related to thermodynamic 
quantities. In this way, few ultra-long simulations are replaced by many short ones, allowing 
one to save valuable computational time. In the earliest implementations, human intervention 
was essential to manually select from where restarting a simulation [58], but in 2014, Doerr 
and De Fabritiis, presented an automated protocol capable of reconstructing the binding 
process for the trypsin-benzamidine system in a totally unsupervised fashion [59]. The 
automated learning method showed to be able to achieve a converged binding affinity one 
order of magnitude faster than classical sampling. They implemented their strategy in a 
freely available environment (known as High Throughput-MD, HTMD [60] that is also 
amenable to replace MSM with other adaptive sampling algorithms) and used it to elucidate 
the cooperative recognition mechanism of ionic cofactors and substrate in the myo-inositol 
monophosphatase enzyme [61], and the binding process of the lipid inhibitor ML056 to 
sphingosine-1-phosphate receptor [62]. The latter is an informative example since described 
the diffusion of the lipophilic ligand ML056 from the bulk solvent to the membrane bilayer 
prior to moving to its orthosteric binding site that is not accessible from the extracellular 
environment like other transmembrane receptors. 
A strikingly different approach is the supervised molecular dynamics (SuMD) protocol 
devised by Sabbadin and Moro [63]. While in adaptive sampling methods seeding is 
employed to resample under-sampled states, in the SuMD implementation, simulations that 
are unlikely to conduct to a productive binding event are discarded on-the-fly through the 
use of a tabu-like algorithm. During short simulations windows, at defined time intervals, 
the distance between the center of masses of the ligand and the binding site is saved and 
subsequently fitted in a linear function. If the slope of the resulting line is negative it means 
that the ligand is moving toward its binding site, and the simulation is evolved. Otherwise, 
the current simulation is interrupted and a new run is restarted from the latest saved 
coordinates through velocity reassignment. Finally, at a user-defined distance value, the 
supervision algorithm is switched off and continuous dynamics is restored. The method has 
been tested against a number of complexes of both globular and membrane proteins [64,65] 
and showed to be effective in reproducing ligand-receptor complexes in the range of 
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nanoseconds. On the other hand, its limitation is the need of an a priori knowledge of the 
binding site location, which, at least in principle, precludes the possibility to discover novel 
and unexplored binding sites like in brute force dynamic docking simulations. Moreover, 
while the protocol has proven valuable in identifying relevant metastable states along the 
recognition process, because of the discontinuous nature of the trajectories, the binding route 
followed by the ligand is not necessarily close to the minimum free energy pathway. 
Similarly, multiscale approaches aim at reducing the time spent by a ligand diffusing in 
the solvent probing its binding site which is not a relevant part of the association pathway. 
The idea behind that is to limit the full atomistic resolution and computationally expensive 
MD simulation only to those regions that are close to the binding site. Very recently, Zeller 
et al. introduced a multiscale approach to Dynamic Docking that also allows the evaluation 
of kinetics of the binding using as test case two H1N1 neuroaminidase inhibitors, oseltamivir 
and zanamivir [66]. Their implementation made use of Brownian Dynamics (BD) [67] when 
the distance between the ligand and the binding site was more than properly defined value. 
Therefore, in this region, ligands and protein are treated as rigid bodies that undergo 
translational and rotational diffusion in an implicit continuum solvent. When the ligand 
reaches the so-called encounter surface, BD switches to all-atom MD and the solvent is 
treated explicitly. They succeeded in reproducing X-ray crystal structures but, as they stated, 
this approach could be useful only for those cases where binding pathways are diffusion 
controlled, having the same usual simulation limitations when the binding involves large 
conformational changes. 
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Author 
(Year) 
Complex 
Multiple 
Ligands 
No. of 
Runs 
Aggregate 
Time 
Productive 
Runs1 
Time to 
Binding 
Brute Force MD 
Shan et al. 
(2011) 
PP1 / Src kinase y 7 115 µs 3 
15.1 / 1.9 / 0.6 
µs 
Dasatinib / Src kinase y 4 35 µs 1 2.3 µs 
Buch et al. 
(2011) 
Benzamidine / 
Trypsine 
n 495 49.5 µs 187 15-90 ns 
Dror et al. 
(2011) 
Dihydroalprenolol / 
β2AR 
y 40 111.8 µs 5 NA 
Alprenolol / β2AR y 10 14 µs 1 NA 
Propranolol / β2AR y 21 35.7 µs 0 - 
Isoprotenerol / β2AR y 1 15.0 µs 0 - 
Dihydroalprenolol / 
β1AR 
y 10 55.5 µs 2 NA 
Kruse et al. 
(2012) 
ACh / M3 R y 1 25 µs 1 9.5 µs 
Tiotropium / M3 R y 3 18 µs 0 - 
Tiotropium / M2 R y 3 16.2 µs 0 - 
Decherchi et al. 
(2015) 
DADMe-immucilin-H 
/ PNP 
y 14 7 µs 3 340 ns 
Discontinuous approaches 
Sabbadin et al. 
(2014) 
ZM241385 / hA2A n 3 - 1 59 ns 
T4G / hA2A n 3 - 1 62 ns 
T4E / hA2A n 3 - 1 105 ns 
Caffeine / hA2A n 3 - 1 15.2 ns 
Cuzzolin et al. 
(2016) 
Ellagic Acid / CK2 n 3 - 0 - 
SAPS / GSTP1-1 n 3 - 2 27 - 19 ns 
Benzen-1,2-diol / 
PRDX5 
n 3 - 3 
17.4 / 31.2 / 18 
ns 
(S)-naproxen / HSA n 3 - 0 - 
(S)-fluoxetin / LeuT n 3 - 0 - 
NECA / hA2A n 3 - 0 - 
Zeller et al. 
(2017) 
Oseltamivir / 
neuraminidase 
n 676 50.0 µs ~20 NA 
Zanamivir / 
neuraminidase 
n 606 35.7 µs ~20 NA 
1 “Productive” refers to simulations that reproduced the crystallographic pose within a given RMSD 
threshold (usually lower than crystal resolution). 
Table 1. Comparative time scales of brute-force MD simulations versus discontinuous approaches 
as reported in retrospective studies. Owing to the inherent difficulties in comparing timescales of 
several short trajectories, works relying on adaptive sampling methods have not been included in 
this table. 
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1.2.2. Enhanced Sampling Methods in Molecular Dynamics 
As shown in the previous paragraph, even though is possible to record and sample a 
binding event using classical MD, these simulations are often too demanding in terms of 
computational cost to be routinely used in the drug discovery and development process. 
Therefore, all the works that have been done seem to be more proofs of concept rather than 
usable and practical tools. Most of the times, because of the large number of the degrees of 
freedom that are needed to be explored and the time spent by the ligand in the bulk solvent 
prior to finding its way to the binding site(s), exploiting these methodologies is not accessible 
with the currently available computational resources. As is often the case with molecular 
dynamics simulations, the system, eventually trapped in a local minimum, is not able to 
overcome the energy barriers and follow the path that separates the absolute minimum 
corresponding to the complex bound state. At the same time, higher energy regions are not 
well sampled so as to make hard to evaluate free energy differences. 
For these reasons, a number of methods, generally referred as enhanced sampling 
methods, have been introduced in order to overcome the energy barriers and improve the 
sampling of the configurational space by using different and, often, elaborate methodologies 
but always relying on a full-atomistic description of the event of interest. For the sake of 
clarity, they can be divided into two categories [30,47]. A first one comprises all the methods 
that enhance the sampling among one of few user-predefined collective variables (CV) 
which are functions of the atomic coordinates, such as metadynamics (MetaD[68]), steered 
MD [69], and umbrella sampling (US, [70]). A second one, in which the configurational 
space is explored at different temperature values or as a function of the potential energy. 
Replica exchange MD (REMD [71]), accelerated MD (aMD [72]), potential scaled MD [73], 
and multicanonical MD (McMD [74]) are examples of methodologies that fall among this 
category. 
Strictly speaking, the strength of the former methodologies is a powerful but complex 
and delicate tool to handle. Seeing that they relying on the user choice of one or more CVs 
(see paragraph 1.3.1., On the Choice of the “Right” CV(s)), they give results that have to be 
carefully evaluated. Moreover, if some important degrees of freedom for the process of 
interest are not taken into account (mainly because a “wrong” set of CVs is chosen), the 
calculated free energy relative to the chosen path can have no physical meaning [47]. 
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Tempering methods, instead, are free from this problematic, as they act on all the degrees of 
freedom of the system at the same time. 
Focusing on the results that have been achieved, the following are some of the cases in 
which enhanced sampling methodologies have been successfully exploited in the dynamic 
docking contest.   
1.2.2.1. Methods Relying on CV(s) 
One of the earliest enhanced sampling methods used to characterize the ligand binding 
process is the metadynamics (MetaD) method introduced by Laio and Parrinello in 2002 
[68]. In MetaD, a history-dependent repulsive potential acting on a few CVs is added to the 
underlying dynamics, discouraging the system from exploring previously visited regions of 
the CV space (Figure 3). In 2005, Gervasio et al. conducted the first application of MetaD 
to ligand binding [75]. To the best of our knowledge, this is the first example of dynamic 
docking. The authors used MetaD to successfully reproduce the binding mode and the 
experimental binding free energy for four complexes:  
 β-trypsin/benzamidine; 
 β-trypsin/chlorobenzamidine; 
 Immunoglobulin McPC-603/phosphocoline; 
 Cyclin-dependent kinase 2 (CDK2)/staurosporine. 
 A few years later, Provasi et al. reported another successful example of the utility of 
MetaD for simulating protein-ligand binding events. Here, they investigated the binding 
pathway of the nonselective antagonist naloxone to the alkaloid binding pocket of a delta 
opioid receptor [76]. Notably, the authors accurately assessed the association constant from 
the free-energy profile reconstructed through MetaD. This was made possible by efficiently 
sampling the ligand in the bulk region, and allowing multiple (un)binding events, which are 
the key to accurately determining the binding free energy. To do so, they confined the 
unbound state of the ligand using a conically-shaped restraint whose contribution to the 
association constant can be taken into account analytically. Similarly, in 2013, Limongelli 
et al. developed the so-called funnel metadynamics, in which the previously described 
confinement is replaced by a funnel-shaped restraint, further reducing the space to explore 
for the ligand in the bulk [77]. Despite the successful results in predicting the mechanism of 
ligand binding, MetaD suffers the same drawbacks of any other CV-based method, i.e., the 
need to choose an optimal set of CVs [78]. Moreover, the simulation time increases 
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exponentially with the number of CVs, and the MetaD performance rapidly deteriorates. 
This makes it difficult to accurately simulate systems characterized by a high degree of 
complexity. In 2007, to overcome these difficulties, Laio et al. developed a new method, 
bias-exchange metadynamics (BS-MetaD), which combines concepts of MetaD and replica 
exchange (see paragraph 1.2.1.2., Methods Relying on Tempering) [79]. In particular, 
multiple MetaD simulations are performed in parallel and exchanged at fixed time intervals. 
Each replica is biased with a time-dependent potential acting on a different CV, thus 
alleviating the problem of CV selection. In 2009, Pietrucci et al. used the BS-MetaD 
technique to successfully describe the binding mechanism of a small peptide to the HIV-1 
protease [80]. Even though the authors accurately computed the free energy associated with 
ligand binding and unbinding as a function of 7 CVs, almost 2 μs of simulation were required 
to converge the free energy. Despite this, they managed to characterize the kinetics of the 
(un)binding process using a discrete-states kinetic model, including the relevant metastable 
states along the recognition pathway. Another variant of MetaD, reconnaissance 
metadynamics (RMD [81]), provides a valid alternative to bias-exchange in considering a 
larger set of CVs. In particular, RMD is a machine-learning approach where the algorithm 
tunes the applied bias using data obtained from short MD simulations. Compared to 
conventional MetaD, this procedure relieves the user of the a priori selection of a small 
number of CVs, and thus provides a way to efficiently explore previously uncharacterized 
mechanisms. In 2012, Soderhjelm et al. applied RMD  to identify and score protein-ligand 
binding poses of the well-known trypsin/benzamidine system [81]. 
 
Figure 3 - In MetaD, a bias is applied to a defined CV (q) in order to fill the underlying free energy 
(F(q)) and discouraging the system to sample already sampled states. 
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1.2.2.2. Methods Relying on Tempering 
Of the various tempering methods, the REMD method has emerged as one of the most 
widely used techniques to enhance conformational sampling [82]. In classical REMD, 
several replicas of the system are simulated independently in parallel, at different 
temperatures. At regular intervals, exchanges between neighboring pairs of replicas are 
attempted according to a Metropolis acceptance criterion (Figure 4). Because an efficient 
exchange requires a significant overlap of the potential energies sampled at adjacent 
temperatures, a high number of replicas is typically required for the method to be effective. 
Hamiltonian REMD (H-REMD), in which the different replicas are simulated at the same 
temperature while the system’s force field is modified, provides a valid alternative to 
temperature REMD. An advantage of H-REMD compared to classical REMD is the 
possibility of varying only part of the Hamiltonian of the system among the replicas, 
improving the exchange probabilities [83]. This computational framework was adopted by 
Luitz et al. to obtain the correct binding modes for protein-ligand systems through explicit 
solvent simulations [84]. In particular, the H-REMD approach was based on softening the 
ligand-protein non-bonded interactions along the replicas in order to prevent the sampling 
of irrelevant states before reaching the native binding mode. The method was tested on three 
different systems: human FKBP protein (FKBP-52) in complex with the high-affinity ligand 
FK506 and with the lower affinity ligand SB3, the peptide-binding domain of murine MHC 
class 1 molecule in complex with a viral antigen. aMD is another enhanced sampling 
technique that does not rely on the a priori definition of CVs. aMD speeds up the 
configurational space sampling by locally adding a non-negative boost potential to the 
system’s potential energy. The potential energy is added only to those regions of the potential 
energy that are below a certain threshold energy value, while leaving those above this level 
unaltered [72]. Recently, Kappel et al. used aMD simulations to simulate processes of ligand 
binding to the M3 muscarinic receptor, a G-protein-coupled receptor (GPCR) [85]. In 
particular, this work used long-timescale aMD simulations (hundred-nanosecond timescale) 
to identify the metastable ligand-binding sites of three known molecules: the antagonist 
tiotropium, the partial agonist arecoline, and the full agonist acetylcholine (ACh). 
Reweighting procedures recover the canonical distribution, from which the free-energy 
landscape can be calculated. However, it is still challenging to estimate the exact population 
for each configuration. This is because the reweighting procedure is subject to a statistical 
error, especially when longer timescales are simulated. In this work, where aMD simulations 
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were performed on the 100–1000 ns timescale, the authors focused on identifying metastable 
ligand-binding sites on the M3 receptor, in agreement with unbiased MD simulations, in a 
significantly shorter time (about 80 times faster for ACh). In 2007, Kamiya et al. provided 
interesting results by performing McMD simulations to successfully dock the inhibitor tri-
N-acetyl-d-glucosamine [86]. McMD is an enhanced sampling method, in which a random 
walk sampling through the energy space is made possible by the bias applied to the system 
[74]. In the McMD method, higher energy states and lower energy states have an equal 
probability of being sampled because different temperature regions defined by the bias are 
simulated simultaneously. A merit of the McMD method is that the canonical ensemble can 
be reconstructed at 300 K relatively easily by a reweighting procedure. Recently, Bekker et 
al. also performed long McMD simulations to dock the inhibitor CS3 to cyclin-dependent 
kinase 2 [87]. To accelerate the reproduction of the native complex, the ligand was restrained 
in a cylindrical region near the binding pocket. In addition, after having identified the correct 
binding mode, they accurately predicted the binding free energy by TI in accordance with 
the experimental data. 
 
Figure 4 – Among the methods that do not rely on CVs, REMD simulates independently several 
replicas of the system at different temperature (T) giving them the possibility to exchange 
coordinates at regular intervals. Background color indicates the Temperature. Rep1-4 are indicated 
with different colors. 
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1.3. The MD-Binding Approach 
1.3.1. On the Choice of the “Right” CV(s) 
As a matter of facts, the possibility of choosing a suitable CV in a molecular dynamics 
simulation represents a practicable way to reduce the complexity of the large number of 
degrees of freedom to a much lower dimensional space [88]. Thus, few simple parameters 
can be either analyzed or manipulated (biasing or “forcing” the system to follow the reaction 
coordinates along this path). However, defining a good (or the so-called “right”) CV for a 
biological process is not a trivial task. The ideal CV has to be representative of the process 
of interest, and capable of describing it in all its aspects without neglecting other important 
variables that have to be taken into account for a complete and effective analysis. In other 
words, the chosen set of CVs may not provide a physical description of the process and of 
the inherent energetics, obtained evaluating the energetic minima and the barriers crossed 
by the system along the specified path[47]. 
Usually, most of the CVs are relative and defined only for a specific issue that one 
wants to address. Some examples can be the torsion angles for analyzing conformational 
changes, the center-of-mass (COM) distance between two sets of atoms, likely a molecule 
and some residues of a binding site in the contest of (un)binding studies, and so on. In 
principle, it is necessary to possess a good and detailed a priori knowledge of the process of 
interest, and this is not common. Moreover, the set of CVs that have proven to be efficacious 
in describing a specific process for one system perhaps is not generally transferable to other 
systems. 
At the same time, every chosen CV has to satisfy a number of conditions[47,68,78]:  
 It has to be function of the coordinates of the system;  
 It has to be defined by a continuous and differentiable mathematical function; 
 It has to be capable of describing all the slow events that are relevant the 
process of interest; 
 It has to be able to discriminate among initial, intermediate and final states. 
 
For all these reasons, choosing a set CV(s) is usually a complex task that hides not few 
difficulties. The choice is mostly related to the experience of the researcher and it is 
conducted on a trial-and-error procedure.  
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Still, in the framework of ligand recognition mechanism, is there a common ground to 
develop a CV that can be extended to every system or, at least, to a vast majority of them? 
Dealing with the case of DADMe-immucillin-H and PNP, Decherchi et al. noticed that the 
driving force of the binding was a strong electrostatic field, due to ligand and binding site 
opposite charges. In a broader perspective, it is well-known the role played by the 
electrostatic interactions in the context of molecular recognition [89–91]. Hence, they started 
to think of a way to take advantage of this electrostatic field even for that cases in which the 
binding event is not naturally driven by electrostatics. 
Under this assumption, they decided to introduce an artificial electrostatic bias 
between the binding partners, i.e. the ligand and a set of residues of the binding site, so as to 
guide the ligand to its target without spending time floating around in the bulk solvent. The 
idea can be exploited introducing fictitious charges on the two sets of interacting atoms with 
a functional form of the type [92]: 
 
𝐶 ∑
𝑄𝑎𝑄𝑏
𝑟𝑎,𝑏
𝑑(𝑟𝑎,𝑏 , 𝜆)
𝑎∈𝐴,𝑏∈𝐵
 (6) 
 
 where A and B are the two interaction partners, and a and b are the atoms comprised 
in A and B, respectively, that are selected by the user, ra,b is the distance between each of 
them, C is a modulation parameter, and 𝑑(𝑟𝑎,𝑏, 𝜆) is a function that modulates the effect of 
the potential according to the distance r and a parameter 𝜆 (see below).  Conventionally, 
these charges Qi have opposite sign and are spread among all the atoms composing each set 
of atoms in order to make the process as natural as possible without forcing unusual 
interactions [92,93]. 
1.3.2. An Adaptive Bias for Ligand Binding 
The next question to address is related to the implementation of this CV in a standardized 
procedure. The ligand has to be guided, rather than “pushed”, to its naturally occurring 
binding mode in a way that the whole procedure is performed as gently as possible avoiding 
unphysical pathways. With this in mind, Spitaleri et al. devised an adaptive behavior of the 
external bias acting on the ligand introducing a series of conditions that have to be satisfied. 
They can be summarized as follows: 
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 The strength of the bias is user-defined but is always kept at a fraction of the 
intensity of the physical forces naturally felt by the ligand; 
 The biasing force is gradually lowered as the process moves forward, which 
means that the ligand is moving to its binding site; 
 Once switched off, the biasing force cannot be turned back on even if the ligand 
leaves the binding site moving further to the solvent. 
 
Mathematically, this is obtained modulating the coefficient C of equation (6) during the 
course of the simulation in a way that the modulus of the additive forces acting on the subset 
of ligand atoms (e.g. 𝑎 ∈ 𝐴) is kept at a predefined fraction of the modulus of the overall 
force originated by the gradient of the regular potential energy of the system. Besides, the 
modulating function 𝑑(𝑟𝑎,𝑏 , 𝜆) of equation (6) assumes the form of an exponential decay 
function: 
 
𝑑(𝑟𝑎,𝑏 , 𝜆) = 𝑒𝑥𝑝 (
−𝑟
𝜆
) (7) 
 
In order to delineate a way to measure the distance from the binding site, they introduced 
the definition of a subset of atoms (?̃?) of the selected residues (𝐵) of the binding site as 
“switching-off” residues. The choice is left to the user and should be guided either by a 
priori knowledge of the system of interest, or by considerations leading the user to 
identifying which pocket residues are potentially relevant  for ligand binding. As an 
example, it can be based on NMR studies or on user assumptions, i.e. one of the deepest 
residues of the binding pocket, for that cases where no data is available. 
The switch-off is obtained via a scaling pre-factor 𝛾 that modulates the biasing force, 
calculated via a switching function as follows [92]: 
 
𝛾 =
1
1 + exp(−𝑠𝑠 ∗ (𝑑𝑖𝑠𝑡 − 𝑡ℎ))
 (8) 
 
where ss and th are two parameters and dist is evaluated as follows [92]: 
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𝑑𝑖𝑠𝑡 = 𝑚𝑖𝑛𝑥∈𝐴𝑚𝑖𝑛𝑦∈?̃?𝑑𝑠(𝑥, 𝑦) (9) 
where ds(x,y) is the pairwise distance between the two atoms x and y. In this way the 
bias is switched-off when any atom of the ligand A falls below a predefined distance from 
any atom belonging to the subset ?̃? of 𝐵. 
It is clear that the user, as is the case with all the methodologies relying on CV(s)-biasing 
and for any SBDD study, should have an idea about the location of the binding site for the 
system of interest. However, the main advantage in respect to a traditional molecular docking 
approach is the possibility of depicting the binding process as a whole, from the ligand in 
the bulk, fully solvated, to the final bound state, without neglecting the eventual metastable 
states. There is also another point that has to be highlighted: it can be done at a fraction of 
the time required by long unbiased MD simulations. 
The protocol is now available in BiKi Life Sciences [94] developed by BiKi 
Technologies. 
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2. Tubulin as a test case 
2.1. Microtubules Structure and Functions 
Microtubules (MTs), together with microfilaments and intermediate filaments, are 
protein polymers composing the cytoskeleton of eukaryotic cells whose main function is 
maintaining cell shape and structure [95]. They serve as a rail for the internal trafficking of 
vesicles and organelles driven by kinesin and dynein motor proteins [96] and play a central 
role in cellular division (mitosis and meiosis), being the major constituents of the mitotic 
spindle, the cellular apparatus responsible of separating sister chromatids.  
MTs are hollow cylindrical polymers built from the lateral association of usually 13 
protofilaments [97] made up of α/β-tubulin heterodimers bound in a head-to-tail fashion (see 
Figure 5 and Figure 6). However, in vitro [98], in bacteria [99] or for other reasons (i.e. the 
interaction with proteins or drugs [100]), it is possible to observe MTs formed by a different 
number of protofilaments.  
In general, the most common assembly is referred as “13-3” [101], where the first 
number, 13, indicates the protofilaments that are bound together to form the MT, and the 
second, 3, the vertical offset between tubulin monomers due to the helicity of the turn. In 
this regard, MTs with different vertical offsets have been observed [102]. This offset 
between tubulins causes a pseudo-helical arrangement with a lattice discontinuity called the 
seam (red line in Figure 7). With respect to its dimensions, for the 13-3 assembly, the MT 
external diameter is about 25 nm whereas the internal about 14 nm. The length varies 
depending on its polymerization status and can reach up to 50 µm [103].  
The order in which tubulin dimers are added to the growing polymer generates a polarity 
at the ends of the resulting structure, which is an essential feature of microtubules. 
Conventionally, the end that is capped by β-tubulin is known as “plus end”, and the other, 
capped by α-tubulin, “minus end” (see Figure 5). These terms arise from the rate of growth 
that takes place at the two ends, which is much faster at the plus end than at the other [102] 
as observed in in vitro studies. In the same context, the polarity of the MT is essential to the 
function of many MAPs (Microtubule-Associated Proteins), which, thanks to this property, 
can recognize the plus end and alter MT dynamics guiding the growth toward specific 
cellular locations, especially during cell division [104]. 
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Figure 5 – Structure of a 15 protofilaments MT generated from the cryo-electron microscopy (cryo-
EM) in complex with the Drosophila melanogaster kinesin-13 KLP10A (PDB ID: 3J2U - 10.8 Å) 
after the removal of the kinesin protein. From the top view (on the left) it is possible to observe the 
internal lumen that is characteristic of MTs. The way tubulin dimers are assembled generates a 
polarity in MT structure (side view, on the right). β-tubulin monomers are depicted in blue 
surfaces, α-tubulin in cyan. 
 
 
 
 
Figure 6 – Tubulin heterodimers. β-tubulin monomers are depicted in blue surfaces, α-tubulin in 
cyan. 
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Inside the cell, MTs are usually anchored through their minus end to the microtubule 
organizing centers (MTOCs), the major of which in animal cells is the centrosome [105]. 
MTOCs serve as an initiation site for MTs growth, where the γ-tubulin ring complex 
(γTuRC, formed by the association of γ-tubulin monomers together with the gamma complex 
associated proteins 2-6 (GCP2-6)) specifically interacts with the MTs minus end. In 
particular, the pseudo-helical-shaped γ-tubulin cap forms strong longitudinal interactions 
with the α-tubulin providing a template for the nucleation of the growing polymer [106]. In 
a broader perspective, nucleation does not always rely on a template and in vivo MAPs, and 
other factors, affect this crucial step [107]. It is worth noting that, in vitro, MTs showed the 
ability to nucleate starting from solutions containing only purified tubulin heterodimers, 
GTP, and Mg2+ ions [108], despite this spontaneous nucleation is a kinetically restrained 
process that requires high tubulin concentrations (for a general view of the process, see 
Figure 7). 
 
Figure 7 – Spontaneous MTs nucleation and growth. The figure depicts the whole process, starting 
from a solution of purified tubulin heterodimers with GTP and Mg2+ (on the left) to the complete 
assembly (on the right). The red line indicates the seam, i.e. the discontinuity in the lattice due to 
the vertical offset between tubulin monomers. 
 
2.2. MTs Dynamic Behavior 
As already mentioned, in order to carry out the functions they are responsible for, MTs 
exploit major conformational changes and go through large variations in their spatial 
arrangement, likely their foremost characteristic, involving a continuous switching between 
polymerization and depolymerization phases. 
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MTs can exert their dynamic behavior through two different mechanisms known as 
treadmilling and dynamic instability.  
Treadmilling (as shown in Figure 8), in a similar manner as for actin filaments, 
involves the addition of tubulin heterodimers at the plus ends of MTs, and the simultaneous 
loss at the minus end. Albeit this process has been observed in vivo [109] and may be 
important in mitosis [110], the resulting biological implications still have to be clarified 
[111] seeing that, inside the cell, most of the time, MTs’ minus end is anchored to the 
MTOCs. In this respect, dynamic instability [112–114], the mechanism that involves the 
addition and the loss of tubulin subunits at the same MTs’ end, appears to be the most 
reasonable and acquires a major role in MTs dynamics. The switch from polymerizing to 
depolymerizing phases is referred as “catastrophe”, the reverse as “rescue” [115]. 
Dynamic instability (Figure 9) is mainly driven by GTP hydrolysis [116]. Going into 
details, each tubulin monomer binds one nucleotide; however, there is a significant 
difference between the two sites. The nucleotide in the α-tubulin site cannot be exchanged 
and cannot be hydrolyzed, therefore it has been called N-site (nonexchangeable-site) 
nucleotide, whereas the one in the β-tubulin is both exchangeable and hydrolyzable, and is 
referred as E-site (exchangeable-site) nucleotide. Tubulin heterodimers can be incorporated 
in the growing filaments only when a GTP molecule is present in both sites. After the 
assembly, only at the level of β-tubulin E-site, GTP is quickly hydrolyzed [117] to GDP, 
which means that MT lattice has an equal concentration of GTP (at the level of α-tubulin N-
site) and GDP. This condition is necessary for MTs depolymerization, as GDP-bound tubulin 
is less stable and promotes depolymerization. For instance, in experiments where GTP has 
been replaced by a slowly hydrolyzable analog (GMPCPP) it has been possible to observe 
MT polymerization but not the subsequent disassembly [116]. 
As a matter of facts, the nucleotide at the N-site is responsible for the curvature of the 
heterodimer: GTP-bound dimers are straighter than GDP-bound ones (for a schematic 
representation see Figure 8) and this feature can somehow explain why the hydrolysis is 
linked to the stability of MTs and the related dynamic capabilities [117]. In addition, for 
reasons that have still to be clarified, in the MT lattice it is possible to find “islands” of GTP-
bound β-tubulin that may act as a trigger for switching from the catastrophe to the rescue 
phase in the context of MTs dynamic instability [117]. 
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Figure 8 – The influence of nucleotide hydrolysis on tubulin dimer curvature and MTs 
treadmilling. GTP-bound tubulin islands (in red, at the center of the MT) may act as a trigger for 
switching among depolymerizing/polymerizing phases. 
 
 
 
Figure 9 - Microtubule dynamic instability. GTP-bound tubulin assembles at the microtubule plus 
end. After GTP hydrolysis occurs, the microtubule becomes unstable and depolymerizes at the 
same end. When GDP is exchanged with GTP in the free tubulin dimers, the cycle can begin again. 
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2.3. MTs bricks: α and β-tubulin 
As it is now evident, tubulin is a highly dynamic entity that can exist in three major 
forms: heterodimers, curved oligomers, and assembled in microtubules. For this and other 
reasons (i.e. the instability of the protein in solution, post-translational modifications and so 
on) gathering three-dimensional (3D) tubulin crystals is a complex task. The first 3D 
structure of the tubulin dimer was reported by Nogales et al. in 1998 [118] obtained by 
electron crystallography (EC) of zinc-induced tubulin sheets stabilized by Taxoetere at a 
resolution of 3.7 Å. The authors were then able to refine their model obtaining a α/β-tubulin 
structure in complex with Taxol at a resolution of 3.5 Å [119] (Figure 10). The use of the 
zinc showed to be a good way of incorporating tubulin dimers in two-dimensional sheets 
[120] that are ideal samples for EC studies. However, the resulting protofilaments, albeit 
similar to those in microtubules, are arranged in an antiparallel way, which, in principle, can 
give rise to artifacts. Nevertheless, the same group was able to dock the above-mentioned 
crystal structure in a 20 Å density map of frozen-hydrated microtubules obtained by cryo-
EM [121]. The 15 protofilaments MT showed to be useful for giving insights into tubulin 
dimer orientation within the MT with respect to the inner lumen, and for identifying lateral 
and longitudinal interactions between other dimers.   
Both α and β-tubulin have a molecular weight of approximately 50 kDa. Each subunit is 
composed of ~450 residues, 40% of which are homologous. The authors [118] proposed to 
divide the structure of each monomer into three functional domains (see Table 2 and Figure 
10), although there were no clear differences in the EC density map. The first domain, the 
N-terminal, constitutes a Rossmann fold [122], typical of those proteins that bind 
nucleotides, therefore called nucleotide-binding domain. The second, a central domain, 
referred as drug-binding domain, which binds Taxol and its derivatives. A final C-terminal 
domain, formed by two helices that within the MT are located on the outer surface, is 
probably involved in the binding of MAPs and motor proteins. The last C-terminal residues, 
consisting of intrinsically disordered tails, were not resolved in the model. Most of the 
differences among different tubulin isotypes (taking human tubulin as an example, there are 
6 isotypes of α-tubulin and 7 of β–tubulin [123]) are located in this region that is also the 
hotspot for a complex series of post-translational modification involved in the regulation of 
MT dynamics [124,125]. These differences give rise to what is now referred as “the tubulin 
code” and more information about it and its implications in various diseases can be found 
elsewhere [126,127]. 
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Residues Name Functions Secondary Structures 
1-205 
Nucleotide-binding 
domain 
Binds the nucleotide GTP/GDP 
6 parallel β-strands (S1-S6) 
6 helices (H1-H6)  
206-381 
Drug-binding 
domain 
Binds Taxol, Colchicine and their 
derivatives 
- 4 β-strands (S7-S10) 
4 helices (H7-H10) Contains the “M-loop” involved in 
lateral contacts between 
protofilaments 
382-end* C-Terminal domain 
Binds MAPs and motor proteins 
- 
2 antiparallel helices (H11-
H12) Hotspot of post-translational 
modifications that give rise to the 
“tubulin code” 
* Residue number is different for α and β-tubulin and may vary among different isotypes. 
Table 2 – Tubulin functional domains 
 
 
Figure 10 – Tubulin in complex with Taxol (PDB ID: 1JFF – 3.5 Å) and GTP (in the α-tubulin, 
down in the picture) and GDP (β-tubulin, up). Functional domains, as reported in [118], are colored 
differently: N-terminal domain in yellow; drug-binding domain in slate blue; C-terminal domain in 
light magenta. 
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A step forward in tubulin structural characterization was represented by the work of 
Knossow and his group [128]. In 2000, they discovered a new way of stabilizing tubulin for 
crystallization. Using the stathmin-like domain of the neural protein RB3 (RB3-SLD), a 
stathmin family protein, they succeeded in obtaining an X-ray structure of two tubulin 
heterodimers in the “curved” conformation. Stathmin proteins are a family of proteins 
involved in the regulation of microtubule dynamics. They are able to inhibit tubulin 
polymerization sequestering two α/β-tubulin heterodimer thanks to their “stathmin-like 
domain” [129,130], and, from another point of view, they can increase the catastrophe rate 
of MTs [131]. 
The T2R structure (T2 stands for two α/β-tubulin heterodimer, R for RB3-SLD) provided 
a clear model for tubulin sequestration by stathmin family proteins. Moreover, the curvature 
of the complex is similar to that of the depolymerization products of MTs bound to GDP, 
suggesting that the binding of the stathmin-like domain does not affect the overall shape of 
curved tubulin protofilaments [131]. 
Figure 11 shows the structural differences between the two complexes. 
 
Figure 11 – Structural differences between heterodimers in straight polymerized protofilaments as 
within microtubules (on the left), and in curved complexes as it happens upon binding of the 
depolymerizing protein stathmin (on the right). 
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Their work paved the way for the further studies that brought to the discovery of almost 
all tubulin binding sites, starting from the colchicine [132] and the vinblastine [133] sites to 
the recent peloruside/laulimalide [134] and maytansine [135] sites. The same can be said 
regarding the tubulin tyrosine ligase (TTL) protein that catalyzes the post-translational re-
tyrosination of detyrosinated α-tubulin, whose molecular mechanism has been elucidated in 
2013 when Prota et al. have solved a T2R-TTL complex [134].  
Indeed, most of these structures rely on the assumption that these drugs can bind to both 
free tubulin and assembled MTs providing only a preliminary and static picture of the 
complex process that is at the basis of their mechanisms of action. 
2.4. Tubulin as Target in Cancer Therapy  
Among all the different cellular functions in which tubulin is involved, from a 
pharmaceutical standpoint, mitosis could be considered the most interesting one. Contrarily 
to the interphase, when MTs turnover (the exchange rate of GDP-bound tubulin dimers with 
soluble GTP-bound ones) is relatively slow, during mitosis, MTs show a much prominent 
dynamic behavior [136]. In particular, during prometaphase, MTs attached to the two 
MTOCs have to grow and shorten quickly and continuously in order to “find” and bind the 
chromosomes at their kinetochores [137] (Figure 12). If only one single chromosome is not 
attached by the MTs of the two MTOCs and is not correctly aligned during the metaphase, 
the cell cannot move to the next phase (anaphase) and, eventually, undergoes apoptosis. 
 
 
Figure 12 – The mitotic spindle [138]. 
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Interfering with MTs dynamic behavior has been proven to be suitable for anticancer 
therapy [139,140] as cancer cells divide more frequently than normal cells, thus they are 
more vulnerable to antimitotic compounds (the so-called “mitotic poisons” that induce 
mitotic arrest and cell death by apoptosis). 
In light of the success of the drugs derived from this class of compounds, one could argue 
that MTs represent the best target for cancer identified so far, and it will continue to be so 
even when more selective approaches will be developed [136]. As a matter of facts, MTs are 
“popular” also among plants (i.e. algae or superior plants as the famous Taxus brevifolia) 
and animals (such as sea hares). They both produce toxic molecules that target MTs 
presumably for self-protective purposes. Besides, most of the antimitotic compounds that 
have been discovered derive from large-scale screens of natural products. It is possible to 
cite the Vinca alkaloids, which were isolated more than 40 years ago from the Catharanthus 
roseus [141], or Taxol, isolated from Taxus brevifolia in 1971 [142]. 
2.5. Chemical Compounds that Interact with Tubulin 
Going into the details, since the first evidences gathered during the seventies, a large 
number of compounds that bind either the free tubulin dimer in solution or the formed MTs 
polymers have been identified. Initially, they were thought to have an influence on MTs 
mass inside the cell but is now clear that is not the case or, at least, the observed effect is an 
indirect consequence of their direct influence on MTs dynamics [143].  
They show large differences in their chemical scaffolds (Table 1Table 3) and act 
through distinct mechanisms of action. For this reason, usually these compounds have been 
classified into two main groups: 
 Microtubule-destabilizing agents (MDAs); 
 Microtubule-stabilizing agents (MSAs). 
MDAs can act in three ways: promoting the depolymerization of the MT; preventing the 
incorporation of tubulin dimers in the growing protofilaments; precluding that the newly 
added tubulin dimer adopt a straight conformation. Within this group fall Vinca alkaloids 
(i.e. vinblastine, vincristine), colchicine, combretastatins, maytansine, rhizoxin and others.  
On the contrary, MSAs promote polymerization and stabilize the polymer, avoiding the 
subsequent depolymerization. They have also the ability to induce the formation of the 
polymer starting from GDP-bound tubulin dimers [144], in contrast to what happens in 
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normal condition. This second category includes Taxol and its derivatives, the epothilones, 
discodermolide, laulimalide, peloruside, etc. 
Despite their different chemical structure (for an overview, see Table 3) and their 
different effects, they all bind only to the β-tubulin subunit. At the time of writing, five 
different binding sites have been identified, which are schematically shown in Figure 13. 
Usually, when discussing MDAs, one can refer to the intradimer interface as the interface 
between α and β-tubulin subunits of the same heterodimer. For example, the colchicine 
binding site is located in proximity of the intradimer interface. In the same way, the 
interdimer interface is the one that lies between two adjacent heterodimers. Vinca alkaloids 
bind at this level and hamper the curved-to-straight transition that is necessary to correctly 
assemble the MT (more detailed lists can be found elsewhere [145–147]). 
 
Figure 13 – The five different binding sites in the β-tubulin subunit. Colchicine (yellow dots) binds 
at the level of the intradimer interface. Vinca alkaloids (dark green dots), such as vinblastine, bind 
at the interdimer interface, so as maytansine-site ligands (purple dots). MSAs, such as taxane-site 
ligands (i.e. Epothilone A, white dots) and peloruside A (lime green dots) bind close to the lateral 
interface between protofilaments. 
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Binding  
Site 
Ligand(s) 
Microtubule-Stabilizing Agents 
Taxane-Site 
 
Taxol 
 
(+)-Discodermolide 
 
Epothilone A 
Peloruside-Site 
 
Peloruside A 
Microtubule-Destabilizing Agents 
Vinca-Site 
 
Vinblastine 
Colchicine-Site 
 
Colchicine 
Maytansine-Site 
 
Maytansine 
 
PM060184 
Table 3 – Examples of molecules that interact with tubulin.  
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From a conceptual perspective, understanding the mechanism of action of the MDAs 
should be, in principle, easier. The molecules that bind to the maytansine-site exert their 
activity inhibiting the addition of further tubulin subunits. Similarly, molecules of the vinca 
domain, as said before, destabilize the MT acting as a wedge.  
The same cannot be said for the MSAs. How do they stabilize the MT? 
2.5.1.  The Taxane-Site 
Taxol, the first microtubule stabilizing agent described in literature [148], is a complex 
diterpenoid isolated from the bark of the tree Taxus brevifolia [142]. Rao et al. first located 
taxol binding site on β-tubulin in 1992 by direct photoaffinity-labelling [149]. Since then, 
many structural works confirmed that taxol binds with a 1:1 stoichiometry in the 
intermediate domain, occupying a site that is closer to the interface between protofilaments 
facing the lumen of the MT (Figure 14) [119,146,150]. 
 
 
Figure 14 – Location of the two MSA sites within the MT shown from the plus-end perspective. 
Taxol binds on β-tubulin (dark grey spheres) facing the lumen of the MT. Peloruside also binds at 
the interface between protofilaments, but facing the external part of the MT. 
 
The binding site, located in the drug-binding domain (Figure 10), is composed by the 
helices H6, H7 (the so-called core helix), part of the helix H1, the β-strand S7 and the loops 
S9-S10 and S7-H9 (Figure 15). The latter is a very long loop, called M-loop for its 
characteristic shape, which is directly involved in the lateral interaction between 
protofilaments [102]. The hypothesis was that the MSAs, pushing the M-loop toward the 
adjacent protofilament, strengthen this interaction avoiding the depolymerization of the MT. 
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Unfortunately, the protofilaments in zinc-stabilized sheets are arranged in an alternating, 
antiparallel fashion. As a consequence, the M-loop interaction that exists within the natural 
MTs assembly cannot be studied correctly. 
 
 
Figure 15 – The tubulin taxane-site when Taxol is bound as in the EC crystal structure (PDB ID: 
1JFF) 
 
Despite the early works based their assumptions on these “artificial” zinc-induced 
tubulin sheets, this theory has been confirmed by the recent x-ray crystallographic studies 
conducted by Prota et al. [135] on others MSAs (Epothilone A and the covalent binder 
zampanolide). Moreover, in 2014, Nogales and co-workers were able to examine the effects 
of taxol binding on MT dynamic behavior using high-res cryo-EM structures (4.7-5.6 Å). 
They noticed that Taxol is able to counteract the effect of GTP hydrolysis reverting the 
conformational changes induced by it [151,152]. Upon taxol binding, GDP-bound MTs 
appear to have the same shape as GTP-bound MTs (they utilized the nonhydrolyzable GTP 
analog, GMPCPP, to reproduce a GTP-like state). However, as they stated, in order to clarify 
the molecular mechanism of this transition further structural analysis at near-atomic 
resolutions are required. 
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 The same group, whose firstly obtained EC structure shed light into tubulin molecular 
details, solved the complex of Epothilone A and tubulin in the same way as they did before 
[151]. However, their results were in a contrast with the first tubulin-bound conformation of 
Epothilone A determined by solution state NMR experiments using a nonpolymerized 
soluble form of α/β-tubulin [153]. For this reason, the binding mode of Epothilone A 
remained elusive until recently, when a high-resolution X-ray crystal structure of the drug 
in complex with a “curved” α/β-tubulin was determined [135] showing clear differences 
from the previously proposed one (Figure 16). Another proof came from the results of Diaz 
and co-workers obtained by Saturation Transfer Difference (STD)-NMR analysis [154], 
which were in agreement with the X-ray model. 
   
 
Figure 16 – Comparison between the originally proposed EP binding mode (on the left, PDB ID: 
1TVK) and the recently one obtained through X-ray (on the right, PDB ID: 4I50). It is possible to 
note how the EC model lacks the necessary resolution to unambiguously assign the position of EP 
atoms, as is the case of the X-ray structure. 
 
In light of these discordant results, a number of questions regarding taxol binding mode 
arise: does the zinc-induced tubulin sheets represent a good model for the straight 
conformation of tubulin? How accurate is the taxol binding mode proposed in 1998?  
At the time of writing, there are still no X-ray structures available to confirm or confute 
the EC structure. New insights can only come from the recent advances in the cryo-electron 
microscopy field. It is now possible to reach near-atomic resolutions that can help in 
portraying the effects of MSAs on the overall MT structure (a recent work from Nogales and 
co-workers, through the use of cryo-EM reconstructions obtained at 3.9-4.2 Å, showed the 
  
49 
effects of taxol and peloruside on the MT lattice [155]). Furthermore, traditional docking 
techniques that rely on inaccurate crystallographic data, cannot deal with such a flexible 
binding site without incurring in the same mistakes [156]. 
For these reasons, exploring the possibilities offered by the recent advances in the 
dynamic docking field could be useful in shedding light on the mechanism of recognition of 
taxane-site ligands. 
2.6. Aims of the Thesis 
Despite MDAs and MSAs have proven to be successful in the clinic treatment of a 
number of different type of cancers, it is not clear why some of them, are so effective against 
certain types of tumors, but basically useless against other types. For example, Taxol is 
routinely used against ovarian, mammary and lung tumors but has no effects on other solid 
tumors, such as kidney, or colon carcinomas. Clearly, some cells are more sensible than 
others to specific antimitotic drugs for a number of reasons that range from the expression 
of diverse protein isotypes to developed resistances [156].  
However, their mechanisms of action is still argument of debate and there are also 
many doubts regarding their specific binding mode. These uncertainties derive from the 
intrinsic difficulties of dealing with a highly dynamic entity, as it is tubulin, a protein with 
the capability of undergoing a transition from a curved to a straight conformation that is a 
consequence of three different forms it can adopt (free soluble dimers, oligomers and 
polymerized in microtubules). Besides, due to the inherent difficulties of obtaining crystal 
structures of the straight conformation of tubulin, the available data is mainly related to the 
curved inhibited conformation of tubulin and, as shown by the case of Epothilone A binding 
mode, this can lead to discordant results. 
From a computational standpoint, dealing with protein flexibility is not easy at all. 
However, in the last years, a number of different methodologies have been implemented to 
bring the study of the molecular interactions to a new level. Molecular dynamics and the 
related enhanced sampling methods are everyday gaining more importance in drug discovery 
and development programs. 
With this in mind, the aim of this project is that of study the binding process of taxane-
site ligands from a fully dynamic perspective. Above all, for unveiling the way these ligands 
exert their stabilizing action on the microtubule, it is necessary to acquire a better 
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understanding of the interactions that are at the basis of the molecular recognizing 
mechanism of these ligands by tubulin. In order to do so, the behavior of the binding pocket 
will be studied by means of classical molecular dynamic simulations. The resulting 
information will be used for the set-up of a fully dynamical protocol through the use of the 
approach recently implemented in the MD-Binding technique. The protocol will then be 
tested against three different ligands (epothilone A, discodermolide, and taxol) of the β-
tubulin taxane-site to evaluate its feasibility and reliability. The relative performances, in 
terms of both strengths and weaknesses, against a traditional static approach, will be 
discussed. 
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3. Material and Methods 
3.1. MD Simulations Setup 
3.1.1. System Preparation 
The protein structural model for the simulations was taken from the experimental 
crystallographic structure accessible at the PDB code 4I4T. Simulations were performed on 
a single α/β-tubulin heterodimer. Therefore, chains A and B, corresponding to the other 
heterodimer, E (stathmin), and F (TTL), were removed along with calcium and chloride ions. 
The GTP and GDP molecules and the Mg2+ ions found in the X-ray structure were included 
in the modelling. The same was done with the covalently bound zampanolide molecule. 
Water molecules involved in the interaction with the Mg2+ ions were maintained. 
Residues of β-tubulin have been renumbered according to the UniProtKB [157] entry 
Q6B856. Therefore, the gaps in the numbering introduced by Lowe et al. [119] based on the 
alignment with the α-tubulin are not present (see APPENDIX: Residue Numbering 
Correspondence for more details). The resulting structure possesses 440 out of 451 residues 
of the α-tubulin (in respect to the UniProtKB P81947) and 431 out of 445 residues of the β-
tubulin (UniProtKB Q6B856). Missing residues belong to the intrinsically disordered C-
terminal domain and haven’t been remodeled. 
An initial guess for missing hydrogens and ambiguous protonation states have been 
evaluated through Schrödinger 2015-2 Protein Preparation Wizard [156] and chosen after a 
visual inspection. The histidine 227 of the helix H7 of taxane-site has been protonated at the 
epsilon position. 
The protein structure has been solvated with TIP3P-model [156] water molecules in a 
truncated octahedron box using 12 Å as minimum distance between the protein and the box 
edges. The system has been neutralized by adding Na+ ions resulting in a total of 123776 
atoms. 
The force field Amber-ff99SB-ILDN [158] has been used for the protein. Parameters for 
MG2+ ions and GTP/GDP molecules have been taken from the AMBER parameter database 
of Bryce Group [156]. MG2+ ions parameters have been developed by Allner et al. [159] 
whereas GTP/GDP parameters by Meagher et al. [160]. Accordingly, the O3 atom type has 
been manually inserted in the leaprc.ff99SBildn force field file. 
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The system has been assembled with the LEaP tool inside AmberTools 14 package [161]. 
Resulting coordinates and topologies files have been converted to GROMACS file formats 
with ACPYPE [162]. 
3.1.2. Plain MD Simulations 
Molecular dynamics (MD) simulations have been performed with GROMACS 4.6.7 
[163]. The prepared system has been minimized with 5000 cycles of the steepest descent 
algorithm. At this point, the system has been equilibrated in four different stages using the 
V-rescale thermostat [164] and the Parrinello-Rahman barostat [165] with a relaxation time 
τ of 2 ps and 0.1 ps, respectively, to keep the system at the desired target temperatures and 
pressure. The first three stages were run for 100 ps each, in the NVT ensemble with an 
integration time step of 1 fs, at increasing temperature values of 100 K, 200 K, 300 K, two 
of which with the backbone heavy atoms harmonically restrained with a force constant of 
1000 kJ/mol/Å2. The last stage was run in the NPT ensemble for 1 ns with an integration 
time step of 1 fs. Bonds involving hydrogen atoms were restrained with the LINCS algorithm 
[166]. A short-range nonbonded cut-off of 9 Å was applied, whereas long-range 
electrostatics were treated with the particle mesh Ewald (PME) method [167]. Periodic 
boundary conditions (PBC) were applied. 
After the equilibration stage, a 100 ns-long classical MD simulation has been conducted 
with an integration time step of 2 fs in the NPT ensemble at a target temperature and pressure 
of 300 K and 1 atm. 
3.2. Binding Pocket Analysis 
Pockets were identified and tracked during the MD simulations by means of the 
Pocketron [168] module implemented in BiKi Life Sciences. For the analysis, the α-tubulin 
subunit, the nucleotides, the ions, and the water molecules were removed. Small and large 
probe radii were set to 1.4 and 3 Å, respectively. Additionally, the minimum volume of a 
detectable pocket was set to the equivalent of 5 water molecules. 
Static pockets and their relative “points of entrance” were evaluated using NanoShaper 
[169] using the same setting as for pocket tracking analysis. 
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3.3. MD-Binding Protocol Setup  
3.3.1. Ligands Parametrization 
3.3.1.1. Epothilone A 
Atomic coordinates of Epothilone A (EP) were taken from the PDB ID 4I50 
corresponding to the X-ray structure of the T2R-TTL-EP complex. The electrostatic 
potential has been computed at the ab-initio HF/6-31G* level theory with NWChem [168], 
as implemented in BiKi Life Sciences in its Residue Parametrization procedure, imposing a 
net charge of 0. The general amber force field (GAFF [170]) was employed to parameterize 
the ligand, while partial charges were fitted using the restrained electrostatic potential 
(RESP) procedure (via Antechamber of AmberTools 14), following the implementation of 
BiKi Life Sciences. 
3.3.1.2. Discodermolide 
No X-ray structure of Discodermolide (DDM) was available at the beginning of this 
study. The isomeric SMILES (simplified molecular-input line-entry system) of (+)-DDM, 
corresponding to the PubChem CID 643668, was used to produce an initial guess of the 3D 
structure by means of the LigPrep utility of Schrödinger Suite 2016-4. The structure has been 
then treated as reported in refs [171,172]. The lowest energy geometry has been obtained by 
conformational search with the MacroModel software (Schrödinger Suite 2016-4). The force 
fields AMBER* and OPLS3 have been used. As searching and minimization algorithms, the 
mixed torsional/low-mode sampling method and the truncated Newton conjugate gradient 
procedure have been used, selecting 40000 structure generation steps (1000 per bond) and 
an energetic cutoff of 29.5 kJ/mol. 
This obtained conformation has been further optimized at the ab-initio HF/6-31G* level 
theory with the Gaussian03 code [173] and relative electrostatic potential has been evaluated. 
As for EP, the general amber force field (GAFF [167]) has been employed to parameterize 
the ligand DDM, while partial charges have been fitted using the RESP procedure via 
Antechamber of AmberTools 14. 
3.3.1.3. Taxol 
Taxol (TAX) structure has been prepared using the same procedure of DDM. The 
isomeric SMILE used corresponds to the PubChem CID 36314. The only difference is 
relative to the QM optimization. Before the optimization at the HF/6-31G* level theory, the 
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initial lowest energy structure derived from the conformational search has been optimized at 
the semi-empirical method AM1 with the Gaussian03 code. 
3.3.2. Ligand(s) Positioning 
The three ligands were placed nearby the binding site using the Reside Placement tool 
of Biki Life Sciences. The binding site pocket has been visually individuated trough VMD 
1.9.3 [174] after the static pocket analysis of the MD frame whose pocket volume resulted 
the highest throughout the entire simulation course (for the relative analysis, see paragraph 
3.2). The relative pocket entrance file has been used and, for the ligands, four different 
starting points and four random rotations were selected. 
The last frame of the MD simulation was selected as protein model; concerning the 
ligands, respectively were used the X-ray model and the optimized conformations, for EP 
and for DDM and TAX. 
3.3.3. Systems Preparation and Equilibration 
The resulting 16 systems for each ligand were prepared using the automated protocol 
implemented in BiKi Life Sciences. The first set of systems consisted each of a dimeric αβ-
tubulin and one EP molecule. The subsequent set of systems included only the β-tubulin 
monomer and one of the ligands of interest among EP, DDM, and TAX. 
System boxes, prepared trough BiKi Life Sciences were then minimized and then 
equilibrated in five different stages, similarly to the tubulin dimeric system described in 
3.1.2. The first two stages consisted of a total simulation time of 200 ps in the NVT ensemble 
at a temperature of 100 K and 200 K respectively. The equation of motion has been 
integrated every 1 fs and the heavy atoms of ligand and protein backbone were restrained. 
The other three stages, instead, were run with a time step of 2 fs. The third and the forth, 100 
ps of simulation each, in the NVT ensemble at 200 K and 300 K, with no restraints on protein 
backbone. The fifth stage was run in the NPT ensemble for 1 ns. In all the equilibration 
stages ligand heavy atom have been restrained. 
3.3.4. MD-Binding Simulations 
MD-Binding Simulations were run with the GROMACS 4.6.1 MD engine patched with 
PLUMED2 [175], ad-hoc modified by BiKi Life Sciences. A series of different settings were 
used to validate the protocol and for productive simulations, which are summarized in Table 
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4. All the simulations were run in the NPT ensemble at 300 K and 1 atm, with an integration 
time step of 2 fs. 
 
Reference 
(Setup) 
Ligand 
Simulation 
Time (ns) 
K_GAIN MAX_K 
Switch-off 
residue(s)2 
Attractive Residues2 
αβ-tubulin heterodimer 
1 EP 15 0.4 NA1 710, 712 
463, 655, 667, 668, 670, 
671, 710, 712, 713, 714, 
719, 722, 723, 724, 798, 
799, 801 
2 EP 15 0.4 NA1 710, 712 
463, 655, 667, 668, 670, 
671, 710, 712, 713, 714, 
798, 799, 801 
3 EP 15 0.4 NA1 712 
655, 664, 668, 710, 713, 
714, 719  
4 EP 15 0.4 NA1 712 
655, 664, 667, 710, 712, 
714, 719 
5 EP 15 0.4 NA1 712 
655, 667, 710, 712, 714, 
719 
6 EP 10 0.4 NA1 712 
655, 667, 710, 712, 714, 
719 
7 EP 10 0.1 0.001 712 
655, 667, 710, 712, 714, 
719 
8 EP 15 0.1 0.001 712 
655, 667, 710, 712, 714, 
719 
9 EP 10 0.2 0.001 712 
655, 667, 710, 712, 714, 
719 
10 EP 15 0.2 0.001 712 
655, 667, 710, 712, 714, 
719 
11 EP 10 0.3 0.00001 712 
655, 667, 710, 712, 714, 
719 
12 EP 15 0.3 0.00001 712 
655, 667, 710, 712, 714, 
719 
β-tubulin monomer 
13 EP 15 0.3 0.00001 272 
215, 227, 270, 272, 274, 
279 
14 DDM 20 0.3 0.00001 272 
215, 227, 270, 272, 274, 
279 
15 TAX 30 0.3 0.00001 272 
215, 227, 270, 272, 274, 
279 
1 NA stands for Not Available. The first version of the algorithm did not have this feature. 
2 Residue number as in the prepared system structures. They differs from the numbering adopted by 
Lowe et al. [119] for the reasons explained in the paragraph 3.1.1. See the appendix for Residue 
Numbering Correspondence. 
Table 4 – Different setups used for MD-Binding simulations used in this work 
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3.3.5. Molecular Docking 
3.3.5.1. Traditional Static Docking 
The software Glide [173] was used to test traditional molecular docking capabilities at 
reproducing the binding mode for the T2R-TTL-EP complex. The receptor grid was 
generated using, as protein conformation, the last frame of the classical MD simulation of 
the αβ-tubulin heterodimer. The grid center was defined as the centroid of residues His667 
and Pro712. Default values were used for vdW radii and electrostatic scaling factors. Protein 
was treated as rigid body and ligand as flexible. For comparison purposes, both Glide scoring 
functions, GLIDE SP (Standard Precision) and GLIDE XP (Extra Precision), have been 
tested in different runs. It has been select to return 20 poses as output of docking calculations 
(the default is 1). 
The ligand structure used has been previously prepared with the LigPrep utility of 
Schrödinger Suite 2016-2. 
3.3.5.2. Induced-Fit Docking 
Induced-Fit docking module implemented in Schrödinger Suite 2016-2 was tested 
against the same protein conformation as for the traditional static docking. The “enhanced” 
protocol has been selected. It consists of an initial Glide SP docking using a softened 
potential (vdW radii scaling factor of 0.5) followed by a Prime [176] Refinement (i.e. the 
minimization of the side-chains of receptor residues) of the obtained complexes and a final 
redocking with the default values for the scaling factors. The grid center was defined as for 
the traditional docking. For the minimization step were included all the residues at 6 Å from 
the ligand.    
3.3.6. Scoring of MD-Binding Poses 
To evaluate MD-Binding poses at the end of the simulations water molecules were 
removed. As suggested by Glide user manual, when selecting the “minimize only” docking 
mode for rescoring purposes, the GLIDE SP scoring function has been chosen. 
3.3.6.1. Rescoring with MM/GBSA 
In order to rescore the poses obtained by the MD-Binding simulations, the protein and 
the ligand of last frames of each trajectory were extracted in two different files and 
subsequently fed to the Prime MM/GBSA module of Schrödinger Suite 2016-2. The 
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OPLS_2005 force field was used along with the VGBSA implicit solvation model [176], the 
one implemented in Prime.  
Protein flexibility has been evaluated minimizing all protein residues at 6.0 Å from 
ligand atoms. 
3.3.7. Figure Preparation 
The figures of this work have been rendered either with the open-source version of Pymol 
1.8.4.0 [177] or with VMD 1.9.3 [174]. Graphs were prepared using Gnuplot 4.6 [178].  
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4. Results and Discussion 
4.1.  Pocket Behavior Investigations 
4.1.1. Model Selection 
The first step in every computational work is the choice of the starting structure. Due to 
the fact that this work is focused on the taxane-site, the chosen protein structure should not 
have any gap in this region. At the same time, in order to investigate dynamic docking 
capabilities in dealing with protein flexibility, it would be preferable to avoid any bias that 
could somehow help the implemented protocol.  
The best-case scenario would be the possibility to have an apo structure of the protein of 
interest. Unfortunately, this does not apply to the tubulin case. As previously introduced, the 
taxane-site is composed by a number of stable helices (H6, H7, and part of H1), and two 
loops, one of which has a very peculiar shape that gives him the name, the so-called “M-
loop”. It is highly flexible and no electron density associated to it is found in the crystal 
structure of the tubulin-stathmin-TTL-apo complex (PDB ID: 4IIJ). It can be stabilized either 
by the lateral interactions with other protofilaments within the MT or by the presence of 
certain MSAs bound to the taxane-site or to the peloruside-site. 
These circumstances reduced the number of possible usable structures to the ones 
summarized in Table 5. 
 
PDB ID Resolution (Å) Ligands Reference 
4I50 2.3 Epothilone A [135] 
4I4T 1.8 Zampanolide [135] 
4O4J 2.2 Peloruside A [134] 
4O4H 2.1 Laulimalide [134] 
4O4I 2.4 Laulimalide – Epothilone A [134] 
4O4L 2.2 Peloruside A – Epothilone A [134] 
Table 5 – αβ-tubulin X-ray structures where the M-loop is present. 
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Avoiding the complexes where epothilone A is present, for the reasons exposed above, 
the structure with the highest resolution is the one where zampanolide occupies the taxane-
site. Despite its side-chain can be superimposed well to that of epothilone A, their macrolidic 
cores are involved in a completely different set of interactions (the planes of the macrocycle 
are oriented at a ~90° angle [135]). In addition, zampanolide is covalently bound to the NE2 
(epsilon nitrogen) atom of His229 of the helix H7 (Figure 17). Indeed, the conformation of 
the amino acids of the binding site is certainly influenced by the bound molecule but, from 
the perspective of this work, this was going to be nothing more than another possibility to 
make things more fascinating. 
 
 
Figure 17 – Zampanolide binding mode as in its X-ray crystal structure (PDB ID: 4I4T – 1.8 Å). 
The ligand is covalently bound to the His 229 of Helix H7. Other than two hydrogens bond with 
the backbone of Thr 276, it is possible to identify many hydrophobic interactions. 
 
We, therefore, decided to use the αβ-tubulin heterodimer of the T2R-TTL-Zampa 
complex, removing the tubulin tyrosine ligase, the other heterodimer lacking the ligand, and 
the stathmin-like domain of RB3. The same was done for the covalently bound zampanolide, 
imposing the His229 (i.e. the one involved in the binding with zampanolide) as epsilon 
protonated. 
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The resulting complex consisting of the two subunits and their relative nucleotide GTP 
or GDP, along with the Mg2+ ions and the water molecules coordinated with them, is 
highlighted in Figure 18. 
 
 
Figure 18 – The selected protein structure for this work. Chains removed from the PDB 4I4T are 
transparent, as it is the ligand zampanolide in the β-tubulin taxane-site. β-tubulin is colored in 
marine blue, α-tubulin in light cyan. 
 
There are no gaps in the selected structure, apart from a number of residues 
corresponding to the C-terminal tails of both subunits, which are known to be intrinsically 
disordered for the reasons explained in paragraph 2.3. These have an influence on MT 
dynamic instability but not on the internal stabilization of the monomers, thus have not been 
remodeled. 
Nevertheless, with the aim of reducing the effects of the ligand in the taxane-site, we 
decided to run a 100 ns-long classical MD simulation of the complex from which select and 
retrieve a sort of apo-like conformation of the protein. In other words, this choice was mainly 
Taxane-site 
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driven by the preliminary condition of getting rid of any bias that could interfere with our 
simulations, both positively and negatively. 
Before going into details, for a better understanding of the results, it is necessary to make 
an annotation regarding the residue numbering. Lowe et al. [118], aligning α and β 
sequences, noticed that in order to match their secondary structures it was necessary to insert 
two gaps into β tubulin primary structure numbering. This is more evident at the level of the 
loop S9-S10, which is eight residues longer in the α-tubulin subunit. As a matter of facts, 
this insertion occupies the taxane-site and explains why no ligands bind at the level of the α-
tubulin monomer. Anyway, for compatibility reasons with the MD engines that have been 
used in this work, we renumbered all the residues based on the correct amino acids sequence 
that is reported in the UniProtKB database (the corresponding ID is Q6B856). Therefore 
binding site residues numbering does not correspond to that reported in literature.  For more 
details, it is possible to find a correspondence table in the APPENDIX. 
4.1.2. Classical MD-Simulation 
In order to gain a deeper understanding of the structural and dynamic behavior of the 
taxol binding site, we ran one 100 ns-long MD simulation in explicit solvent, using the well-
established atomistic force field Amber-ff99SB-ILDN [158]. From the initial conformation, 
the root mean square deviation (RMSD) of the Cα carbons of the complex stabilizes after 
~40 ns, and then oscillates around 1.8 Å for the remaining time of the simulation (Figure 
19A). Considering the two subunits separately, the RMSD of the α-tubulin stabilizes after 
~40 ns, whereas the one of the β-tubulin stabilizes in a much shorter time (~10 ns). After 
this period, the two remain stable around values of ~ 1.5 and 1.25 respectively (Figure 19B-
C). 
It is worth noting that some residues of the intrinsically disordered C-terminal tails are 
still present in both subunits and their contributions must be carefully taken into account 
when computing the RMSD. In order to do so, we calculated the RMSD of the Cα carbons 
of both C-terminal domains with and without considering these residues (Figure 20). As 
expected, the overall shape of the curves is very different, showing a remarkable impact of 
just few residues (five for the α-tubulin and seven for the β-tubulin) on the result, which is 
consistent with the experimental data available [124]. We, therefore, decided to remove them 
from the subsequent analysis in order to provide a much clearer picture of protein stability. 
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Figure 19 - Calculated RMSD of the αβ-tubulin heterodimer (A), α-tubulin (B), and β-tubulin (C) 
subunits from their initial X-ray structure plotted as a function of time. The lightest lines represent 
the effective sampling of the RMSD during the entire simulation, whereas the darkest ones are 
smoothed in order to cut-off the noise. 
 
 
Figure 20 - Calculated RMSD of the C-terminal domains (CTDs) of both subunits from their initial 
X-ray structure plotted as a function of time. The red lines represent the RMSD computed taken 
into account the contribution of the entire CTD, while the blue ones have been obtained removing 
the last disordered residues. 
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Following this observation, we reevaluated independently the RMSD of the Cα carbons 
of the three functional domains (see Table 2 and the Appendix for more information) of both 
subunits. The outcome of the analysis shows an even more reassuring result. Especially when 
considering the β-tubulin monomer (i.e. the one we are more interested into, seeing that it is 
where the taxane-site is located), the three domains are very stable along the entire MD 
simulation.  
 
 
Figure 21 – Calculated RMSD of the Cα carbons of the three domains from their initial X-ray 
structure plotted as a function of time. On the left, the RMSD associated to the α-tubulin subunit. 
On the right, the one of the β-tubulin monomer. 
 
These observations, taken together, indicate that the simulation was long enough to relax 
and equilibrate each tubulin subunit within the heterodimer, giving the ground for the next 
studies. In this perspective, we computed the root mean square fluctuations (RMSF) of β-
tubulin Cα carbons with the aim of identifying the most flexible regions of the protein. 
Again, the shows a situation that is in line with the experimental data. Only two regions 
show an RMSF of around 2.5 Å. One, corresponding to a small loop in the N-terminal 
domain (residues 54-58), and another one that lies in the drug-binding domain (residues 275-
284) and relates to the M-loop that is part of the taxane-site. The latter, once loss the 
stabilizing effect of the interaction with the zampanolide side-chain, started to oscillate 
vigorously as expected (the X-ray structures of the apo protein do not have density associated 
to this loop). 
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Figure 22 – Calculated RMSF of the Cα carbons of the β-tubulin subunit during the simulation. For 
clarity reasons, the data coming from the most flexible C-terminal tails (residues 426-431) has been 
removed. 
 
4.1.3. Tracking the Binding Pocket 
Following the assessment of the overall structural stability of the αβ-tubulin heterodimer, 
we focused our attention on the binding site pocket. The tool pocketron [168] of the BiKi 
Life Sciences suite has been used to analyze pocket dynamics. Its underlying algorithm for 
pocket detection is based on the solvent excluded surface (SES) concept [179] (i.e. the 
Connolly–Richards surface [180], obtained by rolling a spherical probe of a specific radius 
over the van der Waals surface of the biomolecular system). Following its assumptions, 
pockets are identified by calculating the volumetric difference between the regions enclosed 
by two different SESs, generated using two different probe radii, as implemented in 
NanoShaper [169].  
In our analysis, we selected the default values of 1.4 and 3 Å for the probe radii, and, 
additionally, the equivalent of 5 water molecules as cutoff value for the minimum detectable 
volume. These settings have been chosen in order to filter the output and retrieve only those 
pockets that can be considered potential binding sites. Moreover, to reduce the 
computational cost of the analysis, we pre-extracted 1000 snapshots of only the β-tubulin 
subunit from our 100-ns long simulations, at defined time intervals. 
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Starting from the first frame of the simulation, pocketron monitors the evolution of the 
initially identified set of pockets, storing the inherent volumes and the residues that 
constitute them. At the same time, it is able to give information regarding pockets 
interactions, tracking the “merging” and “splitting” events that occur throughout the 
analyzed frames. Essentially, it counts all the times that a particular pocket splits into two 
different ones or, from the other point of view, when two different pockets join together in 
a single one. This analysis lets to examine the influence that a particular pocket can have on 
another one, even a very distant one. 
The selected parameters led to the identification of 36 pockets on the β-tubulin subunit, 
four of which have average volumes greater than 100 Å3 (Table 6). Another interesting 
aspect that has to be evaluated is the persistency of these pockets throughout the simulation, 
which indicates the fraction of the total simulation time in which a particular pocket is 
present. Nine of them were present for more of 40 % of the simulation time. As expected, 
being populated by the GDP, the corresponding binding site (pocket ID 5) was present for 
the entire simulation. Remarkably, we recorded the presence of two pockets in a region to 
whom binds the microtubule-stabilizing agent colchicine (pocket ID 7 and 8 with a 
persistency of about 69 and 90 %, respectively). In this respect, it is worth noting that during 
the simulation the analysis revealed also the presence of the peloruside A binding pocket, 
albeit for only the 15 % of the total time. As a matter of facts, this is another evidence of the 
tremendous power of MD simulations. 
The taxane pocket, or at least the main part of it (pocket ID 4), was stable for the 95.8 % 
of the simulation with an average volume of 363.54 Å3. Close to it, in fact, another smaller 
pocket with a persistency of the 46.3 % is formed by some residues of the M-loop and 
comprises that region in which can accommodate epothilone A side-chain. Considering the 
high flexibility of the loop, as shown by the RMSF analysis (Figure 22), the lower 
persistency value comes not unexpected. Moreover, it is also possible that in some of the 
analyzed frames the two pockets are merged in one single entity, hence the 40 % persistency 
value represents only that fraction of the simulation time in which the two pockets were split. 
To verify this hypothesis we analyzed the merge and splitting events recorded during the 
analysis. 
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Pocket ID Average Volume (Å3) Persistency (%) Notes 
1 19.70 20.1  
2 59.48 46.3 Taxane-site 
3 39.68 40.8  
4 363.54 95.8 Taxane-site 
5 344.49 100.0 GTP/GDP site 
6 109.34 81.0  
7 86.97 68.8 Colchicine-site 
8 81.85 73.8  
9 198.10 89.9 Colchicine-site 
10 16.95 16.7  
11 4.85 6.0  
12 15.62 15.3 Peloruside-site 
13 25.49 29.9  
14 20.04 24.8  
15 0.52 0.7  
16 41.53 38.2  
17 7.24 8.7  
18 3.65 3.5  
19 45.80 44.7  
20 6.28 6.9  
21 0.74 0.9  
22 3.34 3.9  
23 9.35 9.8  
24 1.77 2.3  
25 0.37 0.5  
26 2.74 3.2  
27 0.59 0.8  
28 6.89 7.4  
29 21.66 22.1  
30 0.92 0.9  
31 3.25 3.2  
32 1.20 1.4  
33 4.42 5.2  
34 0.14 0.2  
35 0.14 0.2  
36 5.59 5.9  
Table 6 – Identified pockets and relative average volume and persistency. 
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Figure 23 – Marge matrix of the 36 identified pockets. Values from 0 to 40 represent the merging 
probability between two pockets. For clarity reason, values over 40 have been removed. 
  
We noticed that the two matrices (i.e. representing splitting and merging events) have 
similar values, hence we show only one of them. From the merge matrix represented in 
Figure 23 it is possible to observe a crosstalk between pockets ID 2 and 4, therefore our 
initial guess was somehow correct. 
Nevertheless, the most interesting observation that comes out from this analysis is a 
series of merging events (albeit with a low probability) between pocket ID 4 and 6, the latter 
of which is strongly interconnected with pocket ID 5, that coincides with the GDP binding 
site. Once more, this is another evidence of the efficiency of our MD simulations. The 
experimental data, in fact, shows that when a GTP molecule is hydrolyzed to GDP, the 
induced conformational change causes instability within the MT, especially at the level of 
the lateral interactions between protofilaments [151], in which the M-loop seems to play a 
key role [155].  Moreover, MSAs like the drug taxol, are able to revert the conformational 
change induced by the hydrolysis of GDP [151] restoring and stabilizing these lateral 
interactions. In light of these considerations, it is reasonable to think that it should be 
communications between these pockets. 
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Pockets crosstalk can also be shown visually, as in Figure 24, where each node represents 
the geometric center of the atoms that form the corresponding pocket and the edges indicate 
how often two pockets exchange atoms. 
 
 
Figure 24 - 3D network graph of pocket communication. The nodes represent pockets, and the 
edges indicate communication between two pockets. The thickness of each edge is directly 
proportional to the frequency of the merging events. Only pockets with a persistency greater than 
40 % are shown. 
 
We then focused our attention on the residues at the edge between the two pockets 
forming the taxane-site, pocket ID 4 and 2. These residues may act as a gate, mediating the 
opening and closing of the main pocket, thus modulating the entrance of the different 
ligands. Essentially, some atoms belonging to these residues can be involved in the formation 
of both pockets. Their relative persistency (for those that have it greater than 30%) have been 
Pocket ID 4 and 2  
- 
Taxane-site 
Pocket ID 5 
- 
GDP binding site 
Pocket ID 6 
Pocket ID 7 and 9  
- 
Colchicine-site 
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plotted in Figure 25, where it is possible to observe their relative contributions to the 
formation of both pockets. These are mainly residues belonging to the M-loop, such as 
Arg722, Gln716, Thr714 with long side chains or the smaller Ala723 and Pro712. Therefore, 
we had another confirmation that taxane-site is directly influenced by the flexibility of this 
loop. 
 
 
Figure 25 - Time persistency of residues that define the main taxane pocket (blue bars, pocket ID 4) 
and its correlated pocket (green bars, pocket ID 2). Only residues with a persistency greater than 
30% are shown. 
 
Following this consideration, we monitored the volumes of the two pockets along the 
simulations. We already knew that the main pocket (ID 4) is persistent for the major part of 
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the simulation (Table 6). However, the presence of pocket ID 2, and its volume thereof, is 
correlated to the merging events that occur throughout the simulation (Figure 26). 
 
 
Figure 26 – Volume over time (expressed as frame number) of the two taxane-site pockets (ID 2 
and 4). Light colored lines represent the effective sampling of the volume during the simulation, 
whereas the dark colored ones represent their approximation with a Bezier curve. 
 
We noticed that when the volume of the main pocket increases, the other decreases, and 
vice versa. This behavior is more evident around the 500th frame when the main pocket 
almost vanishes or the frames 350th (35 ns of simulation) and 870th (87 ns) when it is the 
only one to be present. Specifically, the latter is related to a merging event recorded at the 
863rd frame and the subsequent splitting at the 880th. This was the longest lasting period in 
which the two pockets were merged in one entity. 
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4.2. Considerations on the MD-Binding Protocol Setup 
Going back to the traditional docking realm, the first aspect that has to be considered is 
the selection of the protein structure against which perform the docking calculation. 
Sometimes it may be right to select more than one protein model to work with, for example, 
if there are significant conformational shifts due to certain factors, such as the presence of 
other ligands, post-translational modifications, etc. [179].  
For the reasons exposed above, conversely, a fully dynamical approach is free from this 
hurdle. Our 100-ns long simulations, other than for the evaluation of pocket behavior, was 
motivated by the need of getting rid of the binding site conformation induced by the ligand 
zampanolide. We wanted to put the MD-Binding protocol to the test with a challenging 
exercise and, because no complete X-ray structures were available, we regenerated a sort of 
“apo-like” protein status. Thus, we selected as starting structure for the subsequent enhanced 
sampling MD simulations, the last frame of our plain MD simulation. 
Essentially, the MD-Binding protocol follows the workflow illustrated in Figure 27, and 
shares some of its steps to both docking and MD simulations. 
 
 
Figure 27 – MD-Binding workflow. 
 
1
• Localization of binding site pocket
2
• Ligand placement in the simulation box
3
• Minimization 
4
• Equilibration with protein and ligand restrained
5
• Equilibration with ligand restrained
6
• Dynamic docking simulations
7
• Scoring of obtained poses
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As a matter of facts, if from one end the MD-Binding technique overcomes the problems 
related to the selection of the conformation, from the other it introduces a series of delicate 
issues that are needed to be addressed (see paragraph 1.3). Firstly, the ligand molecule has 
to be placed in the simulation box in a way that it can reach its binding site in the user-
selected simulation time (i.e. between 10 and 30 ns). Secondly, the method requires the 
selection and the tuning of a number of parameters: 
 Attractive residue(s) - the residue(s) to whom the bias should be applied; 
 Switching-off residue(s) - the residue(s) whose distance from the ligand 
determines the adaptiveness of the bias; 
 Bias strength. 
 
Regarding the former topic, we used the Residue Placement utility inside BiKi Life 
Sciences. The utility needs a “pocket entrance” file, generated by the NanoShaper static 
pocket detection tool. NanoShaper, in fact, identifies all the possible entrances to the given 
pocket and positions a set of points on each of them. In a second step, these points are 
clustered, and the centroid relative to each cluster is considered as a putative access door of 
the ligand to the pocket. Seeing that it depends from the shape of the relative pocket and that 
the taxane site is highly mutable through the entire simulation, we had to select which frame 
to employ for the static pocket analysis. According to the volume-over-time plot (Figure 26), 
we decided to select one of the frames belonging to the longest lasting period in which the 
two related pockets of the taxane-site were merged in one single entity. Specifically, we 
selected the 875th frame, the one in which we recorded the highest volume for the binding 
site pocket.  
For comparison, Figure 28 shows the different shapes assumed by the pocket in the 875th 
frame (the one used for generating the pocket entrance file) and the last frame of our 
simulation (the one selected as starting point for the subsequent enhanced sampling MD 
simulations). 
Once these access doors have been identified, the utility place a ligand molecule 10 Å 
away from each of them along the normal to the relative point, with a series of different 
random orientations. In our case, we identified 4 points of entrance and selected to use 4 
random ligand orientations. 
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Figure 28 - Pocket volume (showed in blue surface) at different times during the simulation 
generated by NanoShaper. On the left, the 875th frame used for generating the pocket entrance file, 
and, on the right, the last frame of the simulation, where the taxane-site pocket is split into two 
different pockets, therefore pocket ID 4 volume is much smaller. 
 
We then prepared the resulting structures according to the paragraph 3.3.3, restraining 
the ligand heavy atoms during the equilibration steps. We did this in order to avoid having 
it floating around the binding site, invalidating the simulations. 
Regarding the rest of the parameters for the production runs, we based our settings on a 
step-by-step approach. Our first attempts were defined without using any a priori knowledge 
(Reference setups 1, 2 of Table 4). We used as attractive residues, the ones composing the 
taxane pocket at the end of the plain MD trajectory and, as switching off residues, Pro710 
and Phe712. We imposed a simulation time of 15 ns and a K_GAIN of 0.4, the defaults 
values suggested by BiKi Life Sciences. In our first set of simulations, we used the entire 
αβ-tubulin heterodimer. 
We then tested a different sets of atoms for both attractive and switching-off sets of 
residues (Reference setups 3-5 of Table 4) and lowered the K_GAIN parameter to a value 
as minimum as possible to reduce the bias strength and, at the same time, the influence of 
the bias itself on the simulations (Reference setups 6-12 of Table 4). Latest versions of the 
protocol implemented also a MAX_K parameter in order to avoid a too abrupt introduction 
of biasing force at the beginning of the simulations. We tested two different settings for the 
MAX_K parameter (Reference setups 10-12 of Table 4). 
 
  
74 
4.3. Protocol Validation 
In line with any traditional docking workflow, the very first aspect to consider is if the 
implemented protocol is able to recover the experimental binding mode. We had to 
discriminate between the two different epothilone A binding modes, knowing that one of 
them is likely to be incorrect (the EC structure obtained at 2.9 Å, PDB ID: 1TVK) or 
remarkably different from the one adopted in free-tubulin heterodimers, the structure we are 
studying. In the best-case scenario, our protocol should be able to recover only the X-ray 
crystallographic pose (PDB ID: 4I50 – 2.3 Å) or, at least, to recover the X-ray pose a number 
of times higher than the EC one. 
4.3.1. Traditional Docking Procedures 
In this respect, before putting the MD-Binding protocol in place, we verified the 
capabilities of one of the major docking software currently available, Glide [181], to 
reproduce the X-ray pose using as protein conformation the one we previously selected. We 
tested both its scoring function, the standard precision (GLIDE SP) and the extra-precision 
(GLIDE XP). In the same perspective, knowing the importance of the taxane-site flexibility,  
we also tested the induced-fit module [23] implemented in the same suite (Schrödinger Suite 
2016-2). For the induced-fit docking, we did not specify any particular residue but we 
selected to sample side-chains conformations of all the residues within 6 Å of any of the 
ligand atoms, using the “extended sampling” procedure. 
The results did not come unexpected. None of them was able to recover both the X-
ray pose and the EC one. Considering the conformation of the receptor we used (Figure 28, 
on the right), just from a purely visual inspection it seems clear that a molecule like the 
epothilone A cannot fit in such a narrow space. Even the specifically developed induced-fit 
module cannot deal with the large loop rearrangements of the binding site. Thinking on the 
way it works, the first step is always a traditional docking procedure, therefore, the ligand is 
completely flexible whereas the protein is kept rigid. Besides, despite the use of a 
considerable scaling factor for the vdW radii (0.5), it is unreasonable to think that the 
subsequent side-chains rearrangements could produce enough space for the ligand 
accommodation. 
From another standpoint, it is worth noting that, using the protein conformation of the 
X-ray structure (4I50), the Glide algorithm succeeded in the self-docking test, it correctly 
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reproduced the crystallographic binding mode. Once again, this put the emphasis on the 
impact that the selection process of the protein conformations would have in traditional 
docking procedures, especially for those cases where large loop rearrangements are reported 
upon binding. 
4.3.2. The Two Epothilone A Binding Modes at Test 
Proceeding with our studies, we wanted to assess the stability of the two crystallographic 
binding modes. In order to do so, we ran two 100-ns long plain MD simulations starting 
from the two crystal complexes, corresponding to the PDB ID 1TVK and 4I50. From the 
initial conformation, the RMSD of the ligand heavy atoms showed an evident different 
behavior for the two binding modes (Figure 29). 
 
 
Figure 29 - Calculated RMSD of the ligand heavy atoms from their initial crystallographic structure 
plotted as a function of time, after fitting on binding site Cα carbons. 
 
Whereas the X-ray binding mode is stable for the entire simulation (the average RMSD 
value is 1.23 Å), the trend in the RMSD plot for the simulation that started from the EC 
crystallographic structure is typical of an unstable pose (the average RMSD value is 5.78 Å, 
with peaks of 10.46 Å). During the simulation, the macrolidic core of the ligand rotates 
around its center-of-mass (COM) and the side chain, being solvent exposed, does not make 
and durable interaction with the protein. 
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In the same context, it is interesting to note that the RMSF of the β-tubulin Cα carbons in 
the simulation that started from the X-ray complex (Figure 30) is similar to that computed for 
the previously simulated apo-structure with a significant exception. The M-loop region 
(corresponding to residues 272-285) is now less flexible due to the stabilization effect of 
epothilone A (1.5 Å vs 2.5 Å. For comparison, see Figure 22 and Figure 30). Conversely, in the 
simulation that started from the EC complex, the M-loop is way less stable than both the two 
other simulations (5.5 Å vs 1.5 Å - Figure 30). Given the importance of the M-loop in the lateral 
interactions with other protofilaments, and the stabilization effect shown by epothilone A on the 
MT lattice, this can be considered another proof against the validity of the binding mode 
proposed by the EC density map. 
  
 
Figure 30 - Calculated RMSF of the Cα carbons of the β-tubulin subunit during the simulations of 
the two complexes. For clarity reasons, the data coming from the most flexible C-terminal tails 
(residues 426-431) has been removed. 
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4.3.3. Dynamic Docking of Epothilone A 
4.3.3.1. Posing 
We then moved to the analysis of the MD-Binding approach to dynamic docking. We 
ran our simulations through the BiKi Life Sciences interface and monitored the ligand’s 
heavy atoms RMSD against the two crystallographic structures 1TVK and 4I50. 
As stated in paragraph 4.2, we started with a generic approach, selecting all the residues 
of the binding pocket as “attractive residues” and the deepest among them, as “switching-
off residues” (Figure 31 - Reference setups 1 of Table 4.). This kind of approach does not 
exploit any a prori knowledge of the system of interest, apart from the location of the binding 
site itself. From this perspective, looking at the single tubulin heterodimer in solution, the 
taxane-site looks more like a superficial binding site rather than an inner cavity, as it is the 
colchicine-site (Figure 13). 
 
 
Figure 31 – Reference setup 1 of Table 4. Attractive residues are shown in blue, switching-off 
residues in magenta. 
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Our first set of simulations did not recover any of the crystallographic poses (Table 7) 
and we thought that it was due to our residues selection. Despite the adaptiveness of the 
methodology, it seemed to us that the amount of residues we selected attracted the ligand to 
various directions, producing a diffused effect of the virtual charges. 
 
Run ID 
Final RMSD against 
X-Ray Structure (Å) 
Best RMSD against 
X-Ray Structure (Å) 
Best RMSD against 
EC Structure (Å) 
1 6.96 5.27 8.04 
2 10.53 6.78 12.76 
3 4.98 4.06 7.80 
4 8.14 7.44 4.92 
5 7.91 6.77 5.21 
6 9.49 8.26 4.10 
7 8.26 7.82 4.81 
8 6.59 6.22 4.63 
9 9.18 6.33 7.27 
10 9.98 7.97 9.32 
11 9.43 8.13 6.35 
12 6.32 5.56 9.16 
13 9.72 7.94 6.23 
14 7.17 6.21 7.08 
15 15.78 14.7 15.18 
16 8.80 7.71 5.20 
Table 7 – Computed RMSD of the ligand’s heavy atoms during the MD-Binding simulations run 
according to the parameters specified in Table 4 - reference setup 1.  
 
Moreover, it is useful to remember that as soon as any atom of the ligand reaches any of 
the atoms of the switching-off residues (i.e. the pairwise distance between them should be 
less than 4 Å), the bias is gradually lowered and the simulation reaches a plain-MD like 
status. With this in mind, we decided to put a different rationale on the choice of the residues 
trying different setups. We looked at the pocket and, at the end, we imposed as switching-
off residue only the Pro712, avoiding the unnecessary addition of the Phe710. The latter is 
positioned in a way that does not smooth the interaction with the ligand, therefore its 
switching-off control is not exploited. Additionally, we reduced the number of the attractive 
residues to six: Leu655, His667, Phe710, Pro712, Thr714, and Gln719 (Figure 32). 
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Figure 32 - Reference setups 5-12 of Table 4. Attractive residues (Leu655, His667, Phe710, 
Pro712, Thr714, and Gln719) are shown in blue, the switching-off residue Pro712 in magenta. 
 
According to the crystallographic binding mode of PDB ID 4I50, some of these are 
the residues that make contact with epothilone A. We avoided the use of Asp664, despite its 
known interaction with one of two macrocycle hydroxyl groups because, being located at 
the surface of the protein, it has not been identified as part of the pocket by the NanoShaper 
software.  
With these new parameters, in one out of the 16 different runs, we recorded an RMSD 
value as low as 0.69 Å for ligand’s heavy atoms compared to the X-ray crystal structure 
(Table 8). We initially thought to have recovered the X-ray binding mode but, looking more 
carefully at the structure, we noticed some discrepancies. Despite the hydrophobic 
interactions with the pocket wall and the macrolidic part of epothilone A are maintained 
(Phe710, Pro712, Leu668, and Leu655), the M-loop helix induced by the MSA zampanolide 
is now less ordered, and the relative residues are in a different conformation. As illustrated 
in Figure 33, the h-bond between the side chain of Gln719 and the macrocycle hydroxyl 
group does not take place. Instead, Gln719 is involved in another h-bond with the backbone 
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of Leu655. The same can be said for the h-bond between the hydroxyl group of the Thr714 
and the thiazole nitrogen of epothilone A lateral chain. 
 
 
Figure 33 – Comparison between the crystallographic binding mode of epothilone A (top) and the 
one obtained by means of MD-Binding (bottom). Residues with a different conformation (Thr714 
and Gln719) are highlighted in orange. 
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 Run ID 
Final RMSD against 
X-Ray Structure (Å) 
Best RMSD against 
X-Ray Structure (Å) 
Best RMSD against 
EC Structure (Å) 
1 2.78 1.90 7.41 
2 9.18 8.33 4.65 
3 7.97 7.72 5.85 
4 7.31 7.13 5.98 
5 8.34 7.91 9.57 
6 8.54 8.04 9.03 
7 8.93 8.13 4.35 
8 9.00 8.52 4.02 
9 1.08 0.69 8.86 
10 6.64 5.42 6.77 
11 6.63 4.88 7.58 
12 8.17 7.27 5.57 
13 8.69 6.89 5.31 
14 6.55 6.20 7.52 
15 7.97 6.24 7.93 
16 8.80 8.42 4.97 
Table 8 – Computed RMSD of the ligand’s heavy atoms during the MD-Binding simulations run 
according to the parameters specified in Table 4 - reference setup 6.  
 
In light of these results, we considered the possibility to reduce the strength of the 
imposed artificial bias. We, therefore, tested different values for the K_GAIN (0.1, 0.2, and 
0.3) parameter. At the same time, BiKi Life Sciences implemented a new adaptive 
parameter, MAX_K, with the aim of attenuating the effect of the bias at the beginning of the 
simulations and avoiding to have a harsh acceleration for the ligand when it is in the bulk 
solvent.  
With the K_GAIN set to 0.1 and 0.2, we did not recover the X-ray structure. Conversely, 
we found the perfect balance with a K_GAIN value of 0.3 and a MAX_K value of 0.00001. 
With these settings, corresponding to the reference setup 11 and 12 of Table 4 that differs 
only for the simulation time (10 and 15 ns, respectively), succeeded in recovering the 
crystallographic binding mode. Besides, aware of the previous mistake, instead of 
monitoring only the RMSD of ligand’s heavy atom, we included in the computation also the 
backbone of the binding-site residues. This addition produced a better picture of the binding 
event (Table 9) letting us to properly identify the crystallographic binding mode (Figure 34). 
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Run ID 
Final RMSD against 
X-Ray Structure (Å) 
Best RMSD against 
X-Ray Structure (Å) 
Best RMSD against 
EC Structure (Å) 
1 7.44  7.15  6.01 
2 9.20  7.35  11.0 
3 9.85  9.50  9.32 
4 7.42  2.77  8.08 
5 1.61  1.13  7.99 
6 7.07  5.87  7.73 
7 8.58  6.00  5.39 
8 7.03  4.38  8.17 
9 8.59  6.78  5.71 
10 8.79  7.35  5.47 
11 5.02  3.86  8.15 
12 7.43  6.27  6.85 
13 8.90  8.36  6.93 
14 9.83  9.28  8.78 
15 8.97  7.29  3.41 
16 11.89 10.46 11.73 
Table 9 - Computed RMSD of the ligand’s heavy atoms and the backbone of binding-site residues 
during the MD-Binding simulations run according to the parameters specified in Table 4 - 
reference setup 12. 
 
 
Figure 34 – The correctly reproduced binding mode of epothilone A with MD-Binding. Reference 
setup 16 of Table 4, Run ID 5. For comparison, see Figure 33 (top). 
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For comparison, Figure 35 shows the different evolution of the bias (dictated by the 
parameter k) with the above-mentioned two different setups. The introduction of the 
MAX_K value smooths the switching-on of the bias in the first part of the simulation and.  
Its effect is noticeable from the trend of the distance between the ligand and the switching-
off residue. The ligand, in fact, moves slower toward its binding site following a more natural 
behavior. 
 
 
Figure 35 – Evolution of the bias (grey area) for two different MD-Binding setups. The green line 
represents the distance between the ligand and the switching-off residue Pro712 monitored along 
the MD simulations. The red line is the imposed threshold value of 4 Å that controls the bias 
switch-off. 
 
 
4.3.3.2. The importance of the His227 
An interesting observation that came out looking at the simulations is the role played by 
the His227. We noticed that in many different runs, when the ligands struggled to reach the 
crystallographic binding mode, the histidine side-chain was located in a way that prevented 
the proper positioning of the epothilone A macrolidic core. Accordingly, despite the 
interaction with the backbone and the side chain of Thr274 are maintained, allowing the 
correct positioning of the epothilone A lateral chain, the macrocycle assumes a different 
conformation that is unsuitable for establishing the hydrogen bonds with the side chains of 
Asp224 and Gln279. The latter is central to the stabilization of the small M-loop alpha helix, 
which, for this reason, is almost completely unfolded (Figure 36). 
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Figure 36 – The orientation of the His227 is important for the correct positioning of epothilone A 
macrolidic core. His227 is colored in orange when its position, as observed in many MD-Binding 
runs, does not allow the proper positioning of epothilone A. In green, as reported in the 
crystallographic structure (PDB ID: 4I50). 
 
 
4.3.3.3. Scoring 
Staying on the traditional docking analogy, the MD-Binding approach can be seen as the 
searching algorithm. Therefore, it accounts only for the sampling part of the task and needs 
a scoring function to discriminate among all the obtained poses. In principle, one could 
monitor all the interactions that are formed or broken during the course of the simulations, 
rebuild the ligand’s path to binding and evaluate the free energy associated to it. However, 
given the number of obtained poses (and the relative paths), this would have been a 
cumbersome task. Our aim was that of using a docking-like scoring function, fast and easy 
to handle, but enough accurate to weight the different poses. 
We put our attention to the last frames of the MD-Binding simulations, where the bias 
has been switched off and the simulations reached a plain-MD-like status. We extracted the 
protein and the ligand only, and tested the obtained binding mode using a classical docking 
scoring function, the GLIDE SP one, to test its ability of selecting among all the poses, the 
one similar to the X-ray crystal structure. In order to remove any clash between the protein 
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and the ligands, we select to minimize the complex. Moreover, we removed all the waters 
from the computation because, for the way the GLIDE SP scoring function works, they all 
would have been considered as positive interactions, even that waters that are not bridging 
interactions with the protein. The results for the set of simulations run with the reference 
setup 12 (Table 4) are shown in Table 10 where it is possible to note that, according to the 
GLIDE SP score, the best pose has an RMSD value of 7.43 Å in respect to the X-ray crystal 
structure. 
 
Run ID 
RMSD against X-
Ray Structure (Å) 
GLIDE SP Score 
1 7.4408 -4.351 
2 9.2039 -3.465 
3 9.8533 -5.800 
4 7.4249 -4.443 
5 1.6150 -6.591 
6 7.0734 -4.624 
7 8.5892 -3.587 
8 7.0393 -6.486 
9 8.5903 -4.913 
10 8.7936 -2.988 
11 5.0268 -5.193 
12 7.4327 -7.783 
13 8.9014 -4.942 
14 9.8397 -6.338 
15 8.9710 -2.919 
16 11.8945 -3.244 
Table 10 – GLIDE score for the 16 different poses obtained by means of MD-Binding (Table 4 - 
reference setup 12) and the relative RMSD to the X-ray structure (PDB ID: 4I50). The best-scoring 
pose is highlighted in red. The one that is closest to the X-ray structure in green.   
 
For this reason, we decided to use a more accurate scoring function, the Prime 
MM/GBSA approach of the Schrödinger Suite 2016-2. Also for this method, we select to 
optimize all the residues at 6 Å from the ligand in order to avoid steric clashes between the 
ligand and the protein and reduce possible angle deviation from the equilibrium parameters. 
Even though is known that MM-GBSA absolute energy values have no physical 
meaning, in this case, the best-ranked pose is the one that correctly reproduced the 
crystallographic binding mode (Table 11). 
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Rank Run ID 
RMSD against X-
Ray Structure (Å) 
ΔGbind (kcal/mol) 
1 5 1.6150 -72.07 
2 14 9.8397 -71.09 
3 12 7.4327 -68.74 
4 11 5.0268 -62.30 
5 4 7.4249 -57.27 
6 9 8.5903 -56.02 
7 6 7.0734 -55.18 
8 8 7.0393 -54.52 
9 3 9.8533 -52.36 
10 1 7.4408 -51.08 
11 13 8.9014 -49.29 
12 2 9.2039 -44.45 
13 7 8.5892 -42.54 
14 16 11.8945 -41.99 
15 10 8.7936 -41.09 
16 15 8.9710 -39.88 
Table 11 – ΔGbind (kcal/mol) calculated using Prime MM/GBSA method for the 16 different poses 
obtained by means of MD-Binding (Table 4 - reference setup 12) and the relative RMSD to the X-
ray structure (PDB ID: 4I50). 
 
We repeated the analysis for other two set of simulations run with the same setup (Table 
4 - reference 12) and found results in agreement to those above-reported. 
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4.4. Dynamic Docking of Discodermolide and Taxol 
Once validated our protocol with the epothilone A case, we decided to repeat our 
simulations with other two known binders of the taxane-site, discodermolide and taxol. For 
these cases, in order to speed-up the sampling phase, instead of using the whole αβ-tubulin 
heterodimer we used only a β-tubulin monomer. Essentially, in the short time of an MD-
Binding run (10-30 ns), it is unlikely to observe large conformational changes in the protein 
structure. Nonetheless, we re-run a set of MD-Binding simulations for epothilone A and with 
the new setup (Table 4 - reference setup 13), we were able to reproduce the crystallographic 
binding mode and to correctly rank it with MM/GBSA. 
4.4.1. Discodermolide 
At the beginning of this study, conversely to the epothilone A case, no X-ray structures 
of discodermolide were available in the protein data bank. Therefore, we proceeded in a 
similar way as for traditional docking studies. Starting from the 2D structure (see Table 3), 
we generated an initial guess of the tridimensional conformation using the LigPrep utility of 
Schrödinger Suite 2016-4. Due to the high number of degrees of freedom of the molecule, we 
then performed an accurate conformational search with the MacroModel software using the same 
parameters as reported in ref [171,172] that resulted to produce results in agreement with NMR 
studies for the DDM conformation in solution. We further optimized the resulting lowest energy 
structure at the ab-initio HF/6-31G* level theory with the Guassian code and derived the RESP 
partial charges derived as for the epothilone A molecule. 
Despite discodermolide binds at the same site of taxol, there were enough evidences by NMR 
[182], photo labeling [183], and HDX MS (Hydrogen-Deuterium Exchange coupled to Mass-
Spectroscopy) [184] studies, that the two exert their activity through two different mechanisms, 
having different effects on the M-loop stability. After we started our simulations (Table 4 - 
reference setup 14), the X-ray structure of T2R-TTL-DDM complex came out (PDB ID: 
5XLT) [185] and we had the possibility to check the crystallographic binding mode and 
compare it to the one of epothilone A and the one resulted by our simulations. 
As expected, DDM does not make the same interactions as epothilone A. Specifically, 
the former does not interact with the Gln279, and thus it does not stabilize the M-loop to an 
α-helix form. For this reason, there is no density associated to some of the residues of the 
loop in the X-ray crystal structure, similarly to what is reported for the apo form of tubulin, 
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PDB ID 4I55. Besides, DDM interacts with the S9-S10 loop, at the level of the backbone of 
Arg359 (Figure 37). There is also a water-mediated h-bond with the Ser230. 
 
 
Figure 37 – Comparison between the binding mode of DDM (on the left) and EP (on the right) as 
reported in their respective X-ray structures. The highly flexible M-loop, not interacting with 
DDM, is not resolved. 
 
Thanks to the available structure, we were able to monitor the RMSD of the ligand and 
of the binding site residues during the course of our simulations. Looking at the graph (Figure 
38) is possible to note that for a set of 20 simulations, we recovered the X-ray binding mode 
three times.  
 
Figure 38 - Calculated RMSD of DDM and pocket backbone to the X-ray structure (PDB ID: 
5LXT) plotted as a function of time. 
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We then looked carefully at the final poses and noticed a remarkable result: not only all 
the main interaction with the protein were recovered but also the water-mediated hydrogen 
bond with the Ser230 (Figure 39).  
 
 
Figure 39 – The correctly reproduced binding mode of DDM with our MD-Binding protocol ( 
Reference setup 14 of Table 4, Run ID 4). For comparison, see Figure 37 (left). The induced α-
helix is still well folded. 
 
Besides, our simulations provided more information than the static view of the crystal 
structure. We noticed a fluctuation in the hydrogen bond between the nitrogen of the 
backbone of Thr274 and carbonyl group of DDM. This was due to the formation of a weak 
interaction between the carbamate group of DDM and the side-chain of Thr274 (that is not 
present in the X-ray structure). 
Moving to the scoring phase, Prime MM/GBSA resulted useful also in this case. It 
showed to be capable of ranking at the top places all the three simulations whose binding 
mode was closer (in terms of RMSD) to the X-ray crystal structure (PDB ID: 5LXT). The 
results are summarized in Table 12. 
 
Ser230 
Thr274 
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Rank Run ID 
RMSD against X-
Ray Structure (Å) 
ΔGbind (kcal/mol) 
1 20 5.17 -84.94 
2 12 8.28 -76.77 
3 4 6.21 -69.64 
4 5 1.20 -64.34 
5 6 6.01 -56.78 
6 9 6.74 -56.75 
7 14 8.97 -55.48 
8 19 7.55 -52.57 
9 8 9.08 -52.35 
10 1 7.67 -52.29 
11 3 11.4 -50.41 
12 18 1.95 -48.61 
13 11 8.52 -46.31 
14 17 6.93 -43.15 
15 10 8.53 -43.07 
16 7 10.4 -42.06 
17 13 11.2 -38.06 
18 16 8.60 -36.26 
19 2 7.94 -30.81 
20 15 1.77 -30.45 
Table 12 – ΔGbind (kcal/mol) calculated using Prime MM/GBSA method for the 20 different poses 
obtained by means of MD-Binding (Table 4 - reference setup 14) and the relative RMSD to the X-
ray structure (PDB ID: 5LXT). 
 
4.4.2. Taxol 
Lastly, we performed a number of MD-Binding simulations for taxol, starting from the 
optimization of the 2D structure analogously to what we did for discodermolide. Despite the 
low resolution of the available crystal structure (PDB ID: 1JFF – 3.5 Å), the binding mode 
proposed by the authors is in agreement with the results obtained by the photoaffinity 
labeling experiments of a series of taxol analogs [186]. Therefore, we decided to compare 
the outcome our simulations to the binding mode proposed in the 2001 by electron 
crystallography of Zn-induced tubulin sheets (see Paragraph 2.5.1 and Figure 10). 
Specifically, we conducted a series of 30-ns long simulations using the same setup as for EP 
and DDM (Table 4 - reference setup 15). For the comparison, we considered only those 
simulations in which taxol made contact with the switching-off residue Pro272, hence a plain 
MD-like status has been recovered (for visual explanation, see Figure 40). 
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Figure 40 – Comparison of bias and distance evolution during the course of TAX MD-Binding 
simulations. On the left, a simulation in which TAX did not make contact with the switching-off 
residue Pro272; on the right, the bias is completed switched off at about 7 ns, and the simulation 
reached a plain MD-like status. 
 
Unfortunately, none of the simulations recovered the crystallographic binding mode, 
thus we did not proceed to the scoring phase. 
However, visual inspecting our simulations, we noticed that in most of them the bias 
switched off because of the contacts made by one of the lateral phenyl groups, rather than 
by the baccatin main core (Figure 41). 
 
 
Figure 41 – The taxol obtained discordant binding modes. The selected switching-off reside Pro272 
is shown in orange. 
 
In light of these results, we hypothesize that a different selection for the taxol group 
should have been done. In particular, instead of spreading the virtual charges across all the 
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taxol atoms, we should have selected only those forming the baccatin core (Figure 42). In 
analogy to traditional docking techniques, this could resemble, in some way, the constraining 
of a particular set of atoms, a procedure particularly useful when dealing with a congeneric 
series of compounds. 
 
Figure 42 – The taxol baccatin core highlighted in red. 
 
In our case, it could have driven the accommodation of the main core and, after the bias 
switching-off, to the subsequent arrangement of the lateral chains. 
Nonetheless, further simulations and analysis are required. 
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5. Conclusions and Perspectives 
Even though there are no doubts about the importance of the role played by docking 
simulations in discovering and developing novel compounds of pharmaceutical interest, to 
make sense of often-discordant experimental results and to gain a better understating about 
the driving forces of a binding event, a paradigm shift to a dynamical approach is mandatory. 
Proteins are inherently flexible entities and, especially for those cases in which large 
conformational rearrangements are observed upon binding, the static picture provided by 
traditional docking techniques can’t elucidate the mechanisms at the basis of the binding 
process. In line with this reasoning, molecular dynamics and the related enhanced sampling 
methods are everyday gaining more importance and, in the last few years, several 
computational approaches have been developed in order to exploit their potential in drug 
discovery and development programs. 
In this dissertation, we made use of one of these state-of-the-art strategies, the MD-
Binding technique, to devise a protocol for the dynamic docking of taxane-site ligands to 
tubulin, a protein that by its own nature can exist in three major forms: heterodimers, curved 
oligomers, and straight assembled microtubules. We showed that molecular dynamics 
methods, by taking into account protein flexibility of both backbone and side-chains, have 
the capabilities to overcome many of the limitations of which traditional docking techniques 
suffer. 
After an initial plain MD simulation, thanks to which we gathered valuable information 
regarding the behavior of the binding pocket and, specifically, of its highly flexible M-loop, 
we validated our MD-Binding protocol against the remarkable case of epothilone A. Its 
binding mode, in fact, remained elusive until recently, when the high-res X-ray crystal 
structure of the drug in complex with a curved α/β-tubulin heterodimer was determined and 
showed clear differences from the one proposed using EC data of Zn-induced tubulin sheets. 
Our protocol was able to discriminate between the two selecting the correct one. Besides, by 
comparing it with a traditional software, we showed how the MD-Binding approach relieves 
the user by the arduous work of choosing one or more suitable protein conformations against 
which to perform the docking simulations. 
We had similar results for another ligand, discodermolide, but not for the well-known 
microtubule-stabilizing agent taxol. For the latter, although there are no high-res X-ray 
crystal structures to compare with and verify our results, our protocol was not able to select 
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any relevant binding mode for the drug. We, therefore, hypothesized that a less generic 
approach must be evaluated when dealing with a ligand of its size but further simulations 
and analysis are needed. 
In conclusion, our study showed the feasibility and the potential of the MD-Binding 
method in correctly reproducing the binding modes of two highly flexible ligands, epothilone 
A and discodermolide, in the as much flexible binding site of tubulin at a fraction of the time 
that is generally needed by plain MD simulations. However, the scoring phase represents 
still an open issue for every computational method, and further advancements in the field are 
required. Nonetheless, we believe that, with the advent of more powerful hardware 
architectures and of more accurate and efficient algorithms, dynamic docking will take the 
place of traditional methods at any level of drug discovery programs. 
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APPENDIX: Residue Numbering Correspondence 
 
Numbering correspondence for β-tubulin residues. UniProtKB indicates the exact 
amino acids sequence for the Bos Taurus (bovine) tubulin beta-2B chain encoded by the 
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gene TUBB2B. This residue numbering was used throughout the dissertation when referring 
to the monomeric system. In the αβ-tubulin heterodimeric system, the numbering is shifted 
by 440, which is the number of residues of the α-tubulin subunit. 
Lowe et al. introduced two gaps (at the level of residues that colored in red in the 
Table) due to the alignment of α and β tubulin subunits. α-tubulin, this is more evident when 
considering the second gap (Pro360-Arg369), has 9 more residues in the corresponding loop. 
The three protein domains are colored differently for clarity reasons: the N-terminal 
domain in light yellow, the drug-binding domain in light blue, and the C-terminal domain in 
light magenta. 
Secondary structures that create the taxane-site are highlighted.  
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